CYCLOBUTYLCARBOXAMIDES AS NEMATICIDES

The present invention relates to novel cyclobutylcarboxamide compounds, a process for the preparation of these compounds and their use as nematicides.

Cyclobutylcarboxamides are described, for example, in WO 09/043784, WO06/122952,

WO06/122955, WO05/103006, WO05/103004 and WO04/014842.

Novel cyclobutylcarboxamides have now been found characterized by a cis substituted cyclobutyl ring, which show good nematicidal activity.

The present invention thus relates to compounds of the formula (I)

wherein

A represents phenyl or a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen, hydroxy, C1-C4-alkyl, C3-C6-cycloalkyl, C1 -C4-alkoxy, C1 -C4- alkylcarbonyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6- cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl;

each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R4 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy, C2-C6-haloalkenyl, C2-C6 haloalkynyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, cyano, C1 -C4-alkyl or C1 -C4- haloalkyl;

wherein B and A-CO-NR1 are cis to each other on the four-membered ring,

and tautomers/isomers/enantiomers of these compounds.

In the substituent definitions of the compounds of the formula (I), each alkyl moiety either alone or as part of a larger group (such as alkoxy, alkylthio, alkoxycarbonyl and alkylcarbonyl) is a straight or branched chain and is, for example, methyl, ethyl, n-propyl, n-butyl, isopropyl, sec-butyl, isobutyl, tert- butyl, pentyl, / ^' so-pentyl or n-hexyl. The alkyl groups are suitably C1 -C4-alkyl groups. Alkenyl and alkynyl moieties can be in the form of straight or branched chains, and the alkenyl moieties, where appropriate, can be of either the (E)- or (Z)-configuration. Examples are vinyl, allyl and propargyl. Alkenyl and alkynyl moieties can contain one or more double and/or triple bonds in any combination. Preferably, the alkenyl and alkynyl moieties contain 2 to 6, more preferably 3 or 4 carbon atoms.

Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.

Haloalkyl groups are alkyl groups which are substituted with one or more of the same or different halogen atoms and are, for example, CF ₃ , CF ₂ CI, CF ₂ H, CCI ₂ H, FCH ₂ , CICH ₂ , BrCH ₂ , CH ₃ CHF, (CH ₃ ) ₂ CF, CF ₃ CH ₂ or CHF ₂ CH ₂ .

Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cycloalkyl is preferably cyclopropyl or cyclobutyl.

The term "heteroaryl", "heteroaromatic ring" or "heteroaromatic ring system" refers to aromatic ring systems containing at least one heteroatom and consisting either of a single ring or of two fused rings. Preferably, single rings will contain up to 3 and bicyclic systems up to 5 heteroatoms, which will preferably be chosen from nitrogen, oxygen and sulphur. Examples of such groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,3,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1 ,2,3-triazinyl,

1 ,2,4-triazinyl, 1 ,3,5-triazinyl, benzofuryl, benzisofuryl, benzothienyl, benzisothienyl, indolyl, isoindolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, 2,1 ,3- benzoxadiazole, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,

naphthyridinyl, benzotriazinyl, purinyl, pteridinyl and indolizinyl.

Compounds of the formula (I) can occur in at least two enantiomeric forms: (laa) and (lab). B and A-CO-NR1 are cis to each other in each of these enantiomers (laa) and (lab). The difference between (laa) and (lab) is that the two carbon atoms bearing the B and the A-CO-NR1 groups each have their absolute stereochemistr formally inverted.

(I) (laa) (lab) relative stereochemistry absolute stereochemistry absolute stereochemistry

The trans isomers of compounds of formula (I), wherein B and A-CO-NR1 are trans to each other on the four-membered ring, can be formed as side products in the synthesis of compounds of the formula (I). Mixtures containing up to 50%, preferably up to 40%, more preferably up to 30%, especially up to 20%, advantageously up to 10%, desirably up to 5%, in particular up to 3 %, of the trans isomer are understood to be also part of this invention,, such as any one of compounds of formulae (I), and each relevant intermediate described herein therefor. Compounds of formula (lab) are novel and also form part of the invention. Preferred defintions of A, B and R1 described herein for compounds of formula (I) also apply to compounds of formula (lab).

It is possible that compounds of the formula (I) have further stereochemical centres in one or more of the substituents. Further isomers are then possible. The invention covers all such isomers and mixtures thereof.

The compounds of the formula (I) may occur in different tautomeric forms. The invention covers all those tautomeric forms and mixtures thereof.

The following list provides definitions, including preferred definitions, for substituents A, B, R1 , R2, R3, R4 and R5 with reference to compounds of formula (I). For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.

A represents phenyl or a 5- or 6-membered heteroaromatic ring containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3.

Preferably, A represents phenyl or a 5- or 6-membered heteroaromatic ring containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3.

More preferably, A represents phenyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, thienyl or furyl, wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3.

Even more preferably, A represents phenyl, pyridyl, pyrazinyl or pyrazolyl wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3.

Most preferably, A represents phenyl optionally substituted by one R2, 2-pyrazinyl, 2-pyridyl or 3- pyridyl wherein the pyrazinyl and pyridyl are optionally substituted by one R3.

Preferably, in the embodiments described above, A represents 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 4- pyrimidyl, 2-pyrazinyl, 4-pyrazolyl, 2-thienyl, 3-thienyl, 2-furyl or 3-furyl, as may be appropriate.

In an instance, there are 1 to 3 substitutents R2 or R3 on A. Preferably, A is substituted by one or two of such substituents, most preferably, A is substituted by one substitutent R2 or R3. The preferable point or points of attachment of these substituents is ortho to the point of attachment of A to C(0)NR1 .

B represents naphthyl optionally substituted by one or more R4.

Preferably, B is optionally substituted by one to three R4.

More preferably, B is optionally substituted by one or two R4.

B may be attached to the cyclobutly moiety in via either of the attachment points shown below:

R1 represents hydrogen, hydroxy, C1-C4-alkyl, C3-C6-cycloalkyl, C1 -C4-alkoxy, C1 -C4- alkylcarbonyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6- cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl.

More preferably, R1 represents hydrogen, C1 -C4-alkyl, C3-C4-cycloalkyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6-cycloalkylcarbonyl, C3-C6- cycloalkoxycarbonyl or benzyl.

Most preferably, R1 is hydrogen

In another group of compounds according to formula (I), R1 preferably represents hydrogen, hydroxy, C1 -C4-alkyl, C1 -C4-alkoxy, C1 -C4-alkylcarbonyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2- C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6-cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl.

More preferably in this group of compounds according to formula (I), R1 represents hydrogen, C1 -C4-alkyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6- cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl.

Most preferably in this group of compounds according to formula (I), R1 is hydrogen.

Each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio.

Preferably, each R2 independently of one another represents halogen, methyl, difluoromethyl or trifluoromethyl.

More preferably, each R2 independently of one another represents halogen or trifluoromethyl.

Even more preferably, each R2 independently of one another represents trifluoromethyl.

In another group of compounds, each R2 is most preferably halogen.

Each R3 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl,

C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio.

Preferably, each R3 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4- haloalkyl.

More preferably, each R3 independently of one another represents halogen, C1 -C2-alkyl or C1 -C2-haloalkyl. Even more preferably, each R3 independently of one another represents chloro, bromo, methyl, difluoromethyl or trifluoromethyl.

More preferably again, each R3 independently of one another represents chloro, bromo, methyl or trifluoromethyl.

Most preferably, each R3 independently of one another represents chloro or trifluoromethyl.

Each R4 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy, C1 -C4-alkylsulfanyl, C1 -C4-haloalkylsulfanyl, C1 -C4-alkylsulfinyl, C1 -C4-haloalkylsulfinyl, C1 -C4-alkylsulfonyl, C1 -C4-haloalkylsulfonyl, C2-C6-haloalkenyl, C2-C6 haloalkynyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5.

Preferably, each R4 independently of one another represents halogen, cyano, C1 -C4-haloalkyl,

C1 -C4-haloalkoxy, C2-C6-haloalkenyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5.

More preferably, each R4 independently of one another represents halogen, cyano, C1 -C4- haloalkyl, C1 -C4-haloalkoxy or C3-C6-cycloalkyl optionally substituted by one or more substituents R5.

Even more preferably, each R4 independently of one another represents halogen or

trifluoromethyl.

Most preferably, each R4 independently of one another represents halogen.

Each R5 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl or C1 -C4-alkoxycarbonyl.

Preferably, each R5 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4- haloalkyl.

More preferably, each R5 independently of one another represents halogen or trifluoromethyl.

In one group of compounds according to formula (I), A represents phenyl or a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen, hydroxy, C1 -C4-alkyl, C1 -C4-alkoxy, C1 -C4-alkylcarbonyl, C1 -C4- alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6-cycloalkylcarbonyl, C3-C6- cycloalkoxycarbonyl or benzyl;

each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R4 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl,

C1 -C4-alkoxy, C1 -C4-haloalkoxy, C2-C6-haloalkenyl, C2-C6 haloalkynyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, cyano, C1 -C4-alkyl or C1 -C4- haloalkyl; wherein B and A-CO-NR1 are cis to each other on the four-membered ring.

In another group of compounds according to formula (I), A represents phenyl or a 5- or 6- membered heteroaromatic ring containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen, hydroxy, C1-C4-alkyl, C3-C6-cycloalkyl, C1 -C4-alkoxy, C1 -C4- alkylcarbonyl, C1 -C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -C4-cyanoalkyl, C3-C6- cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl;

each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl,

C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R4 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy, C2-C6-haloalkenyl, C2-C6 haloalkynyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, cyano, C1 -C4-alkyl or C1 -C4- haloalkyl;

wherein B and A-CO-NR1 are cis to each other on the four-membered ring.

In another group of compounds according to formula (I), A represents phenyl or a 5- or 6- membered heteroaromatic ring containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein the phenyl is optionally substituted by one or more R2 and the heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl, optionally substituted by one or more R4;

R1 represents hydrogen, C1 -C4-alkyl, C1-C4-alkoxycarbonyl, C2-C4-alkenyl, C2-C4-alkynyl, C1 -

C4-cyanoalkyl or C3-C6-cycloalkylcarbonyl, C3-C6-cycloalkoxycarbonyl or benzyl;

each R2 independently of one another represent halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represent halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R4 independently of one another represent halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy, C2-C6-haloalkenyl, C2-C6 haloalkynyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, cyano, C1 -C4-alkyl or C1 -C4- haloalkyl.

In another group of compounds according to formula (I), R1 is hydrogen. In this group of compounds, A, B, R1 , R2, R3, R4 and R5 are as described herein for a compound of formula (I). In another group of compounds according to formula (I), A represents phenyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, thienyl or furyl, wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl; each R4 independently of one another represents halogen, cyano, C1 -C4-haloalkyl, C1 -C4- haloalkoxy, C2-C6-haloalkenyl or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl. Preferably in this group of compounds, A represents phenyl, 2, -pyridyl, 3-pyridyl, 2-pyrimidyl, 2- pyrazinyl, 2-thienyl, 3-thienyl, 2-furyl or 3-furyl, wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3.

In another group of compounds according to formula (I), A represents phenyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, thienyl or furyl, wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen, cyano, C1 -C4-alkyl, C1 -C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy or C1 -C4-haloalkylthio;

each R3 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl; each R4 independently of one another represents halogen, cyano, C1 -C4-haloalkyl, C1 -C4- haloalkoxy or C3-C6-cycloalkyl optionally substituted by one or more substituents R5;

each R5 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl. Preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 4- pyrimidyl, 2-pyrazinyl, 2-thienyl, 3-thienyl, 4-pyrazolyl, 2-furyl or 3-furyl, wherein the phenyl is optionally substituted by one to three R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one to three R4.

In another group of compounds according to formula (I), A represents phenyl, pyridyl, pyrazinyl or pyrazolyl wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen or trifluoromethyl;

each R3 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl; each R4 independently of one another represents halogen or trifluoromethyl. Preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrazinyl or 4- pyrazolyl, wherein the phenyl is optionally substituted by one or two R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4.

In another group of compounds according to formula (I), A represents phenyl, pyridyl, pyrazinyl or pyrazolyl wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one or more R3;

B represents naphthyl optionally substituted by one or more R4;

R1 represents hydrogen;

each R2 represents trifluoromethyl;

each R3 independently of one another represents halogen, C1 -C4-alkyl or C1 -C4-haloalkyl; each R4 independently of one another represents halogen.

Preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrazinyl or 4- pyrazolyl, wherein the phenyl is optionally substituted by one or two R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4.

In another group of compounds according to formula (I), A represents phenyl, 2-pyridyl, 3- pyridyl, 2-pyrazinyl or 4-pyrazolyl wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen or trifluoromethyl;

each R3 independently of one another represents halogen, C1 -C2-alkyl or C1 -C2-haloalkyl; each R4 independently of one another represents halogen or trifluoromethyl.

Preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrazinyl or 4- pyrazolyl wherein the phenyl is optionally substituted by one R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen or trifluoromethyl;

each R3 independently of one another represents halogen, methyl, difluoromethyl or trifluoromethyl;

each R4 independently of one another represents halogen or trifluoromethyl.

More preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrazinyl or 4-pyrazolyl wherein the phenyl is optionally substituted by one R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 independently of one another represents halogen or trifluoromethyl; each R3 independently of one another represents halogen, methyl or trifluoromethyl;

each R4 independently of one another represents halogen or trifluoromethyl.

In another group of compounds according to formula (I), A represents phenyl, 2-pyridyl, 3- pyridyl, 2-pyrazinyl or 4-pyrazolyl wherein the phenyl is optionally substituted by one or more R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 represents trifluoromethyl;

each R3 independently of one another represents halogen, C1 -C2-alkyl or C1 -C2-haloalkyl; each R4 independently of one another represents halogen.

Preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2-pyrazinyl or 4- pyrazolyl wherein the phenyl is optionally substituted by one R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 represents trifluoromethyl;

each R3 independently of one another represents halogen, methyl, difluoromethyl or trifluoromethyl;

each R4 independently of one another represents halogen.

More preferably in this group of compounds, A represents phenyl, 2-pyridyl, 3-pyridyl, 2- pyrazinyl or 4-pyrazolyl wherein the phenyl is optionally substituted by one R2 and each heteroaromatic ring is optionally substituted by one to three R3;

B represents naphthyl optionally substituted by one or two R4;

R1 represents hydrogen;

each R2 represents trifluoromethyl;

each R3 independently of one another represents halogen, methyl or trifluoromethyl;

each R4 independently of one another represents halogen.

Compounds of formula (I) may be prepared by reacting a compound of formula (II)

in which R1 and B is defined under formula (I); with an acylating agent of formula (III)

A-C(=0)-R* (IN),

in which A is as defined under formula (I), and R* is halogen, hydroxy or Ci_ ₆ alkoxy, preferably chloro, in the presence of a base, such as triethylamine, Hunig base, sodium bicarbonate, sodium carbonate, potassium carbonate, pyridine or quinoline, but preferably triethylamine, and generally in a solvent, such as diethylether, TBME, THF, dichloromethane, chloroform, DMF or NMP, for between 10 minutes and 48 hours, preferably 12 to 24 hours, and between 0° C and reflux, preferably 20 to 25 °C. Compounds of formula (II) are novel and also form part of the invention. Preferred defintions of B and R1 described herein for compounds of formula (I) also apply to compounds of formula (II). When R* is hydroxyl, a coupling agent, such as benzotriazol-l -yloxytris(dimethylamino)

phosphoniumhexafluorophosphate, bis-(2-oxo-3-oxazolidinyl)-phosphinic acid chloride (BOP-CI), Ν,Ν'-dicyclohexylcarbodiimide (DCC) or 1 ,1 '-carbonyl-diimidazole (CDI), may be used.

Compounds of the formula (lie) in which B is as defined under formula (I) can be prepared from the ketone (XVIII) wherein B is as defined under formula (I). This can be done by conversion to the oxime (XIX) wherein B is defined under formula (I) and reduction. D. E. Nichols et al. (J. Med. Chem 1984, 27, 1 108-1 1 ) describe methods for this reduction. Certain methods may yield trans isomers as side-products.

(XVIII) (He)

(XIX)

For preparing all further compounds of the formula (I) functionalized according to the definitions of A, B, R-i , R ₂ , R3, R4, R5 and R ₆ there are a large number of suitable known standard methods, such as alkylation, halogenation, acylation, amidation, oximation, oxidation and reduction. The choice of the preparation methods which are suitable are depending on the properties (reactivity) of the substituents in the intermediates.

The reactants can be reacted in the presence of a base. Examples of suitable bases are alkali metal or alkaline earth metal hydroxides, alkali metal or alkaline earth metal hydrides, alkali metal or alkaline earth metal amides, alkali metal or alkaline earth metal alkoxides, alkali metal or alkaline earth metal acetates, alkali metal or alkaline earth metal carbonates, alkali metal or alkaline earth metal dialkylamides or alkali metal or alkaline earth metal alkylsilylamides, alkylamines, alkylenediamines, free or N-alkylated saturated or unsaturated cycloalkylamines, basic heterocycles, ammonium hydroxides and carbocyclic amines. Examples which may be mentioned are sodium hydroxide, sodium hydride, sodium amide, sodium methoxide, sodium acetate, sodium carbonate, potassium tert- butoxide, potassium hydroxide, potassium carbonate, potassium hydride, lithium diisopropylamide, potassium bis(trimethylsilyl)amide, calcium hydride, triethylamine, diisopropylethylamine,

triethylenediamine, cyclohexylamine, N-cyclohexyl-N,N-dimethylamine, Ν,Ν-diethylaniline, pyridine, 4- (N,N-dimethylamino)pyridine, quinuclidine, N-methylmorpholine, benzyltrimethylammonium hydroxide and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

The reactants can be reacted with each other as such, i.e. without adding a solvent or diluent. In most cases, however, it is advantageous to add an inert solvent or diluent or a mixture of these. If the reaction is carried out in the presence of a base, bases which are employed in excess, such as triethylamine, pyridine, N-methylmorpholine or Ν,Ν-diethylaniline, may also act as solvents or diluents. The reaction is advantageously carried out in a temperature range from approximately -80°C to approximately +140°C, preferably from approximately -30°C to approximately +100°C, in many cases in the range between ambient temperature and approximately +80°C.

A compound of formula (I) can be converted in a manner known per se into another compound of formula (I) by replacing one or more substituents of the starting compound of formula (I) in the customary manner by (an)other substituent(s) according to the invention.

Depending on the choice of the reaction conditions and starting materials which are suitable in each case, it is possible, for example, in one reaction step only to replace one substituent by another substituent according to the invention, or a plurality of substituents can be replaced by other substituents according to the invention in the same reaction step.

Salts of compounds of formula (I) can be prepared in a manner known per se. Thus, for example, acid addition salts of compounds of formula (I) are obtained by treatment with a suitable acid or a suitable ion exchanger reagent and salts with bases are obtained by treatment with a suitable base or with a suitable ion exchanger reagent. A salt is chosen depending on its tolerances for compound's use, such as agricultural or physiological tolerance.

Salts of compounds of formula (I) can be converted in the customary manner into the free compounds (I), acid addition salts, for example, by treatment with a suitable basic compound or with a suitable ion exchanger reagent and salts with bases, for example, by treatment with a suitable acid or with a suitable ion exchanger reagent.

Salts of compounds of formula (I) can be converted in a manner known per se into other salts of compounds of formula (I), acid addition salts, for example, into other acid addition salts, for example by treatment of a salt of inorganic acid such as hydrochloride with a suitable metal salt such as a sodium, barium or silver salt, of an acid, for example with silver acetate, in a suitable solvent in which an inorganic salt which forms, for example silver chloride, is insoluble and thus precipitates from the reaction mixture.

Depending on the procedure or the reaction conditions, the compounds of formula (I), which have salt-forming properties can be obtained in free form or in the form of salts.

Diastereomer mixtures or racemate mixtures of compounds of formula (I), in free form or in salt form, which can be obtained depending on which starting materials and procedures have been chosen can be separated in a known manner into the pure diasteromers or racemates on the basis of the physicochemical differences of the components, for example by fractional crystallization, distillation and/or chromatography.

Enantiomer mixtures, such as racemates, which can be obtained in a similar manner can be resolved into the optical antipodes by known methods, for example by recrystallization from an optically active solvent, by chromatography on chiral adsorbents, for example high-performance liquid chromatography (HPLC) on acetyl celulose, with the aid of suitable microorganisms, by cleavage with specific enzymes, via the formation of inclusion compounds, for example using chiral crown ethers, where only one enantiomer is complexed, or by conversion into diastereomeric salts, for example by reacting a basic end-product racemate with an optically active acid, such as a carboxylic acid, for example camphoric, tartaric or malic acid, or sulfonic acid, for example camphorsulfonic acid, and separating the diastereomer mixture which can be obtained in this manner, for example by fractional crystallization based on their differing solubilities, to give the diastereomers, from which the desired enantiomer can be set free by the action of suitable agents, for example basic agents.

Pure diastereomers or enantiomers can be obtained according to the invention not only by separating suitable isomer mixtures, but also by generally known methods of diastereoselective or enantioselective synthesis, for example by carrying out the process according to the invention with starting materials of a suitable stereochemistry.

N-oxides can be prepared by reacting a compound of the formula (I) with a suitable oxidizing agent, for example the H ₂ 0 ₂ /urea adduct in the presence of an acid anhydride, e.g. trifluoroacetic anhydride. Such oxidations are known from the literature, for example from J. Med. Chem., 32 (12), 2561 -73, 1989 or WO 00/15615 or C. White, Science, vol 318, p.783, 2007.

It can be advantageous to isolate or synthesize in each case the biologically more effective isomer, for example enantiomer or diastereomer, or isomer mixture, for example enantiomer mixture or diastereomer mixture, if the individual components have a different biological activity.

The compounds of formula (I) and, where appropriate, the tautomers thereof, in each case in free form or in salt form, can, if appropriate, also be obtained in the form of hydrates and/or include other solvents, for example those which may have been used for the crystallization of compounds which are present in solid form.

Tables 1 to 1 12: Compounds of formula (IA) and Compounds of formula (IB)

The invention is further illustrated by making available the following individual compounds of formula (IA) listed below in Tables 1 to 56 and the following individual compounds of formula (IB) listed below in tables 57 to 1 12..

Each of Tables 1 to 56, which follow the Table P below, make available 54 compounds of the formula (IA) in which B is the substituent defined in Table P and A is the substituent defined in the relevant Table 1 to 56. Thus Table 1 individualises 54 compounds of formula (IA) wherein for each row of Table P, the A substituent is as defined in Table 1 ; similarly, Table 2 individualises 54 compounds of formula (IA) wherein for each row of Table P, the A substituent is as defined in Table 2; and so on for Tables 3 to 56. Each of Tables 57 to 1 12, which follow the Table P below, make available 54 compounds of the formula (IB) in which B is the substituent defined in Table P and A is the substituent defined in the relevant Table 57 to 1 12. Thus Table 57 individualises 54 compounds of formula (IB) wherein for each row of Table P, the A substituent is as defined in Table 57; similarly, Table 58 individualises 54 compounds of formula (IB) wherein for each row of Table P, the A substituent is as defined in Table 58; and so on for Tables 59 to 1 12.

Table P

Compound B

No.

P.001 naphthalen-2-yl

P.002 6-bromo-naphthalen-2-yl

P.003 6-Fluoro-naphthalen-2-yl

P.004 6-chloro-naphthalen-2-yl

P.005 6-methyl-naphthalen-2-yl

P.006 4-bromo-1 -fluoro-naphthalen-2-y

P.007 1 -bromo-7-chloro-naphthalen-2-yl

P.008 1 -bromo-7-fluoro-naphthalen-2-yl

P.009 1 -bromo-5-fluoro-naphthalen-2-yl

P.010 5,6,7-trifluoro-naphthalen-2-yl

P.01 1 1 -bromo-5-chloro-naphthalen-2-yl

P.012 4-chloro-naphthalen-2-yl

P.013 4-bromo-naphthalen-2-yl

P.014 3-chloro-naphthalen-2-yl

P.015 3-fluoro-naphthalen-2-yl

P.016 1 -chloro-naphthalen-2-yl

P.017 1 -fluoro-naphthalen-2-yl

P.018 1 -bromo-naphthalen-2-yl

P.019 8-chloro-naphthalen-2-yl

P.020 8-fluoro-naphthalen-2-yl

P.021 8-Bromo-naphthalen-2-yl

P.022 7-methoxy-naphthalen-2-y

P.023 6-methoxy-naphthalen-2-yl

P.024 6-cyano-naphthalen-2-yl

P.025 7-cyano-naphthalen-2-yl

P.026 5-fluoro-naphthalen-2-yl

P.027 5-bromo-naphthalen-2-yl

P.028 5-chloro-naphthalen-2-yl

P.029 3-bromo-naphthalen-2-yl

P.030 6-methyl-naphthalen-2-yl

P.031 6-trifluoromethyl-naphthalen-2-yl

P.032 naphthalen-1 -yl

P.033 6-methyl-naphthalen-1 -yl

P.034 4-methyl-naphthalen-1 -yl

P.035 4-fluoro-naphthalen-1 -yl

P.036 4-chloro-naphthalen-1 -yl

P.037 4-bromo-naphthalen-1 -yl

P.038 4-trifluoromethyl-naphthalen-1 -yl

P.039 4-methoxyl-naphthalen-1 -yl

P.040 5-methyl-naphthalen-1 -yl

P.041 5-chloro-naphthalen-1 -yl Compound B

No.

P.042 5-fluoro-naphthalen-1 -yl

P.043 5-bromo-naphthalen-1 -yl

P.044 5-trifluoromethyl-naphthalen-1 -yl

P.045 4-cyano-naphthalen-1 -yl

P.046 5-cyano-naphthalen-1 -yl

P.047 2-chloro-naphthalen-1 -yl

P.048 2-bromo-naphthalen-1 -yl

P.049 2-fluoro-naphthalen-1 -yl

P.050 3-chloro-naphthalen-1 -yl

P.051 3-bromo-naphthalen-1 -yl

P.052 6-bromo-2-methoxy-naphthalen-1 -yl

P.053 3-cyano-7-fluoro-naphthalen-1 -yl

P.054 3-cyano-6-fluoro-naphthalen-1 -yl

Table 1 provides 54 compounds of formula (IA), wherein A is

(2,6-difluorophenyl) wherein the broken line indicates the point of attachment of the group A to the amide group, and B is as defined in each row of Table P. For example, compound 1 .001 has the following structure:

Table 2 provides 54 compounds of formula (IA) wherein A is 2-chloro-3-pyrazinyl (A2) and B is as defined in each row of Table P.

CI > . N

Table 3 provides 54 compounds of formula (IA) wherein A is 3-trifluoromethyl-2-pyridyl (A3) and B is as defined in each row of Table P.

Table 4 provides 54 compounds of formula (IA) wherein A is 3-chloro-2-pyridyl (A4) and B is as defined in each row of Table P.

Table 5 provides 54 compounds of formula (IA) wherein A is 2-trifluoromethyl-3-pyridyl (A5) and B is as defined in each row of Table P.

Table 6 provides 54 compounds of formula (IA) wherein A is 2-trifluoromethyl-phenyl (A6) and B is as defined in each row of Table P.

Table 7 provides 54 compounds of formula (IA) wherein A is 2-chloro-3-pyridyl (A7) and B is as defined in each row of Table P.

Table 8 provides 54 compounds of formula (IA) wherein A is 2-fluoro-6-trifluoromethyl-phenyl (A8) and B is as defined in each row of Table P.

Table 9 provides 54 compounds of formula (IA) wherein A is 2-tolyl (A9) and B is as defined in each row of Table P.

Table 10 provides 54 compounds of formula (IA) wherein A is 2-pyrimidinyl (A10) and B is as defined in each row of Table P.

Table 1 1 provides 54 compounds of formula (IA) wherein A is 3-methyl-2-pyridyl (A1 1 ) and B as defined in each row of Table P.

Table 12 provides 54 compounds of formula (IA) wherein A is 2-fluorophenyl (A12) and B is as defined in each row of Table P.

Table 13 provides 54 compounds of formula (IA) wherein A is 2-chlorophenyl (A13) and B is as defined in each row of Table P.

Table 14 provides 54 compounds of formula (IA) wherein A is 2-bromophenyl (A14) and B is as defined in each row of Table P.

Table 15 provides 54 compounds of formula (IA) wherein A is 2-iodophenyl (A15) and B is as defined in each row of Table P.

Table 16 provides 54 compounds of formula (IA) wherein A is 2,6-dichlorophenyl (A16) and B is as defined in each row of Table P.

Table 17 provides 54 compounds of formula (IA) wherein A is 2-chloro-6-fluoro-phenyl (A17) and

B is as defined in each row of Table P.

Table 18 provides 54 compounds of formula (IA) wherein A is 2,4,6-trifluorophenyl (A18) and B is as defined in each row of Table P.

Table 19 provides 54 compounds of formula (IA) wherein A is 2-trifluoromethoxy-phenyl (A19) and B is as defined in each row of Table P.

Table 20 provides 54 compounds of formula (IA) wherein A is 2-fluoro-6-methyl-phenyl (A20) and B is as defined in each row of Table P.

Table 21 provides 54 compounds of formula (IA) wherein A is 2-fluoro-6-methoxy-phenyl (A21 ) and B is as defined in each row of Table P.

Table 22 provides 54 compounds of formula (IA) wherein A is 2-methyl-3-pyridyl (A22) and R-i , R13, R54 and R15 are as defined in each row of Table P.

Table 23 provides 54 compounds of formula (IA) wherein A is 3-fluoro-2-pyridyl (A23) and B is as defined in each row of Table P.

Table 24 provides 54 compounds of formula (IA) wherein A is 3-methyl-2-pyrazinyl (A24) and B is as defined in each row of Table P.

Table 25 provides 54 compounds of formula (IA) wherein A is 3-bromo-2-pyrazinyl (A25) and B is as defined in each row of Table P.

Br

N N

Table 26 provides 54 compounds of formula (IA) wherein A is 3-trifluoromethyl-2-pyrazinyl (A26) and B is as defined in each row of Table P.

Table 27 provides 54 compounds of formula (IA) wherein A is 2-methyl-3-furyl (A27) and B is as defined in each row of Table P.

Table 28 provides 54 compounds of formula (IA) wherein A is 5-chloro-4-pyrimidinyl (A28) and B is as defined in each row of Table P.

Table 29 provides 54 compounds of formula (IA) wherein A is 2-cyanophenyl (A29) and B is as defined in each row of Table P.

Table 30 provides 54 compounds of formula (IA) wherein A is 2-trifluoromethylthio-phenyl (A30) and B is as defined in each row of Table P.

Table 31 provides 54 compounds of formula (IA) wherein A is 3-bromo-2-pyridyl (A31 ) and B is as defined in each row of Table P.

Table 32 provides 54 compounds of formula (IA) wherein A is 5-bromo-thiazolyl (A32) and B is as defined in each row of Table P.

Table 33 provides 54 compounds of formula (IA) wherein A is thiophenyl 2-trifluoromethyl- thiophenyl (A33) and B is as defined in each row of Table P.

Table 34 provides 54 compounds of formula (IA) wherein A is 2-iodo-thiophenyl (A34) and B is as defined in each row of Table P.

Table 35 provides 54 compounds of formula (IA) wherein A is 2-chloro-thiophenyl (A35) and B is as defined in each row of Table P.

Table 36 provides 54 compounds of formula (IA) wherein A is 3-bromo-thiophenyl (A36) and B is as defined in each row of Table P.

Table 37 provides 54 compounds of formula (IA) wherein A is 3-chloro-thiophenyl (A37) and B is as defined in each row of Table P.

Table 38 provides 54 compounds of formula (IA) wherein A is 2-bromo-thiophenyl (A38) and B is as defined in each row of Table P. Table 39 provides 54 compounds of formula (IA) wherein A is 4-methyl-[1 ,2,3]thiadiazolyl (A39) and B is as defined in each row of Table P.

Table 40 provides 54 compounds of formula (IA) wherein A is 2-cyclopropyl-thiophenyl (A40) and B is as defined in each row of Table P.

Table 41 provides 54 compounds of formula (IA) wherein A is 2-bromo-thiophenyl (A41 ) and B is as defined in each row of Table P.

Table 42 provides 54 compounds of formula (IA) wherein A is 5-methyl-isoxazolyl (A42) and B as defined in each row of Table P.

Table 43 provides 54 compounds of formula (IA) wherein A is 5-cyclopropyl-isoxazolyl (A43) and B is as defined in each row of Table P.

Table 44 provides 54 compounds of formula (IA) wherein A is 2-(trifluoromethyl)furan-3-yl (A44) and B is as defined in each row of Table P.

Table 45 provides 54 compounds of formula (IA) wherein A is 2-bromofuran-3-yl (A45) and B as defined in each row of Table P. Br

Table 46 provides 54 compounds of formula (IA) wherein A is 4-(trifluoromethyl)pyridazin-3-yl (A46) and B is as defined in each row of Table P.

Table 47 provides 54 compounds of formula (IA) wherein A is 3,6-difluoro-2-(trifluoromethyl) phenyl (A47 and B is as defined in each row of Table P.

Table 48 provides 54 compounds of formula (IA) wherein A is 2-bromo-3,6-difluorophenyl (A48) and B is as defined in each row of Table P.

Table 49 provides 54 compounds of formula (IA) wherein A is 2-chloro-3,6-difluorophenyl (A49) and B is as defined in each row of Table P.

Table 50 provides 54 compounds of formula (IA) wherein A is 4-(trifluoromethyl)pyrimidin-5-yl (A50) and B is as defined in each row of Table P.

Table 51 provides 54 compounds of formula (IA) wherein A is 4-(trifluoromethyl)pyrid-3-yl (A51 ) and B is as defined in each row of Table P.

Table 52 provides 54 compounds of formula (IA) wherein A is 3-(difluoromethyl)-1 -methyl- pyrazol-4-yl (A52) and B is as defined in each row of Table P.

Table 53 provides 54 compounds of formula (IA) wherein A is 4-methyloxazol-5-yl (A53) and B is as defined in each row of Table P.

Table 54 provides 54 compounds of formula (IA) wherein A is 3-methoxypyrid-2-yl (A54) and B is as defined in each row of Table P.

Table 55 provides 54 compounds of formula (IA) wherein A is 2-chlorofuran-3-yl (A55) and B is as defined in each row of Table P.

Table 56 provides 54 compounds of formula (IA) wherein A is 2-iodofuran-3-yl (A56) and B is as defined in each row of Table P.

Table 57 provides 54 compounds of formula (IB), wherein A is 2,6-difluorophenyl (A1 as defined in table 1 ) and B is as defined in each row of Table P.

Table 58 provides 54 compounds of formula (IB) wherein A is 2-chloro-3-pyrazinyl (A2 as defined in table 2) and B is as defined in each row of Table P.

Table 59 provides 54 compounds of formula (IB) wherein A is 3-trifluoromethyl-2-pyridyl (A3 as defined in table 3) and B is as defined in each row of Table P. Table 60 provides 54 compounds of formula (IB) wherein A is 3-chloro-2-pyridyl (A4 as defined in table 4) and B is as defined in each row of Table P.

Table 61 provides 54 compounds of formula (IB) wherein A is 2-trifluoromethyl-3-pyridyl (A5 as defined in table 5) and B is as defined in each row of Table P.

Table 62 provides 54 compounds of formula (IB) wherein A is 2-trifluoromethyl-phenyl (A6 as defined in table 6) and B is as defined in each row of Table P.

Table 63 provides 54 compounds of formula (IB) wherein A is 2-chloro-3-pyridyl (A7 as defined in table 7) and B is as defined in each row of Table P.

Table 64 provides 54 compounds of formula (IB) wherein A is 2-fluoro-6-trifluoromethyl-phenyl (A8 as defined in table 8) and B is as defined in each row of Table P.

Table 65 provides 54 compounds of formula (IB) wherein A is 2-tolyl (A9 as defined in table 9) and B is as defined in each row of Table P.

Table 66 provides 54 compounds of formula (IB) wherein A is 2-pyrimidinyl (A10 as defined in table 10) and B is as defined in each row of Table P.

Table 67 provides 54 compounds of formula (IB) wherein A is 3-methyl-2-pyridyl (A1 1 as defined in table 1 1 ) and B is as defined in each row of Table P.

Table 68 provides 54 compounds of formula (IB) wherein A is 2-fluorophenyl (A12 as defined in table 12) and B is as defined in each row of Table P.

Table 69 provides 54 compounds of formula (IB) wherein A is 2-chlorophenyl (A13 as defined in table 13) and B is as defined in each row of Table P.

Table 70 provides 54 compounds of formula (IB) wherein A is 2-bromophenyl (A14 as defined in table 14) and B is as defined in each row of Table P.

Table 71 provides 54 compounds of formula (IB) wherein A is 2-iodophenyl (A15 as defined in table 15) and B is as defined in each row of Table P.

Table 72 provides 54 compounds of formula (IB) wherein A is 2,6-dichlorophenyl (A16 as defined in table 16) and B is as defined in each row of Table P.

Table 73 provides 54 compounds of formula (IB) wherein A is 2-chloro-6-fluoro-phenyl (A17 as defined in table 17) and B is as defined in each row of Table P.

Table 74 provides 54 compounds of formula (IB) wherein A is 2,4,6-trifluorophenyl (A18 as defined in table 18) and B is as defined in each row of Table P.

Table 75 provides 54 compounds of formula (IB) wherein A is 2-trifluoromethoxy-phenyl (A19 as defined in table 19) and B is as defined in each row of Table P.

Table 76 provides 54 compounds of formula (IB) wherein A is 2-fluoro-6-methyl-phenyl (A20 as defined in table 20) and B is as defined in each row of Table P.

Table 77 provides 54 compounds of formula (IB) wherein A is 2-fluoro-6-methoxy-phenyl (A21 as defined in table 21 ) and B is as defined in each row of Table P.

Table 78 provides 54 compounds of formula (IB) wherein A is 2-methyl-3-pyridyl (A22 as defined in table 22) and B is as defined in each row of Table P. Table 79 provides 54 compounds of formula (IB) wherein A is 3-fluoro-2-pyridyl (A23 as defined in table 23) and B is as defined in each row of Table P.

Table 80 provides 54 compounds of formula (IB) wherein A is 3-methyl-2-pyrazinyl (A24 as defined in table 24) and B is as defined in each row of Table P.

Table 81 provides 54 compounds of formula (IB) wherein A is 3-bromo-2-pyrazinyl (A25 as defined in table 25) and B is as defined in each row of Table P.

Table 82 provides 54 compounds of formula (IB) wherein A is 3-trifluoromethyl-2-pyrazinyl (A26 as defined in table 26) and B is as defined in each row of Table P.

Table 83 provides 54 compounds of formula (IB) wherein A is 2-methyl-3-furyl (A27 as defined in table 27) and B is as defined in each row of Table P.

Table 84 provides 54 compounds of formula (IB) wherein A is 5-chloro-4-pyrimidinyl (A28 as defined in table 28) and B is as defined in each row of Table P.

Table 85 provides 54 compounds of formula (IB) wherein A is 2-cyanophenyl (A29 as defined in table 29) and B is as defined in each row of Table P.

Table 86 provides 54 compounds of formula (IB) wherein A is 2-trifluoromethylthio-phenyl (A30 as defined in table 30) and B is as defined in each row of Table P.

Table 87 provides 54 compounds of formula (IB) wherein A is 3-bromo-2-pyridyl (A31 as defined in table 31 ) and B is as defined in each row of Table P.

Table 88 provides 54 compounds of formula (IB) wherein A is 5-bromo-4-thiazolyl (A32 as defined in table 32) and B is as defined in each row of Table P.

Table 89 provides 54 compounds of formula (IB) wherein A is 2-trifluoromethyl-3-thienyl (A33 as defined in table 33) and B is as defined in each row of Table P.

Table 90 provides 54 compounds of formula (IB) wherein A is 2-iodo-3-thienyl (A34 as defined in table 34) and B is as defined in each row of Table P.

Table 91 provides 54 compounds of formula (IB) wherein A is 2-chloro-3-thienyl (A35 as defined in table 35) and B is as defined in each row of Table P.

Table 92 provides 54 compounds of formula (IB) wherein A is 3-bromo-2-thienyl (A36 as defined in table 36) and B is as defined in each row of Table P.

Table 93 provides 54 compounds of formula (IB) wherein A is 3-chloro-2-thienyl (A37 as defined in table 37) and B is as defined in each row of Table P.

Table 94 provides 54 compounds of formula (IB) wherein A is 2-bromo-3-thienyl (A38 as defined in table 38) and B is as defined in each row of Table P.

Table 95 provides 54 compounds of formula (IB) wherein A is 4-methyl-5thiadiazolyl (A39 as defined in table 39) and B is as defined in each row of Table P.

Table 96 provides 54 compounds of formula (IB) wherein A is 4-cyclopropyl-5-thiadiazolyl (A40 as defined in table 40) and B is as defined in each row of Table P.

Table 97 provides 54 compounds of formula (IB) wherein A is 3-methyl-4-isothiazolyl (A41 as defined in table 41 ) and B is as defined in each row of Table P. Table 98 provides 54 compounds of formula (IB) wherein A is 5-methyl-4-isoxazolyl (A42 as defined in table 42) and B is as defined in each row of Table P.

Table 99 provides 54 compounds of formula (IB) wherein A is 5-cyclopropyl-4-isoxazolyl (A43 as defined in table 43) and B is as defined in each row of Table P.

Table 100 provides 54 compounds of formula (IB) wherein A is 2-(trifluoromethyl)furan-3-yl (A44 as defined in table 44) and B is as defined in each row of Table P.

Table 101 provides 54 compounds of formula (IB) wherein A is 2-bromofuran-3-yl (A45 as defined in table 45) and B is as defined in each row of Table P.

Table 102 provides 54 compounds of formula (IB) wherein A is 4-(trifluoromethyl)pyridazin-3-yl (A46 as defined in table 46) and B is as defined in each row of Table P.

Table 103 provides 54 compounds of formula (IB) wherein A is 3,6-difluoro-2-(trifluoromethyl) phenyl (A47 as defined in table 47) and B is as defined in each row of Table P.

Table 104 provides 54 compounds of formula (IB) wherein A is 2-bromo-3,6-difluorophenyl (A48 as defined in table 48) and B is as defined in each row of Table P.

Table 105 provides 54 compounds of formula (IB) wherein A is 2-chloro-3,6-difluorophenyl (A49 as defined in table 49) and B is as defined in each row of Table P.

Table 106 provides 54 compounds of formula (IB) wherein A is 4-(trifluoromethyl)pyrimidin-5-yl (A50 as defined in table 50) and B is as defined in each row of Table P.

Table 107 provides 54 compounds of formula (IB) wherein A is 4-(trifluoromethyl)pyrid-3-yl (A51 as defined in table 51 ) and B is as defined in each row of Table P.

Table 108 provides 54 compounds of formula (IB) wherein A is 3-(difluoromethyl)-1 -methyl- pyrazol-4-yl (A52 as defined in table 52) and B is as defined in each row of Table P.

Table 109 provides 54 compounds of formula (IB) wherein A is 4-methyloxazol-5-yl (A53 as defined in table 53) and B is as defined in each row of Table P.

Table 1 10 provides 54 compounds of formula (IB) wherein A is 3-methoxypyrid-2-yl (A54 as defined in table 54) and B is as defined in each row of Table P.

Table 1 1 1 provides 54 compounds of formula (IB) wherein A is 2-chlorofuran-3-yl (A55 as defined in table 55) and B is as defined in each row of Table P.

Table 112 provides 54 compounds of formula (IB) wherein A is 2-iodofuran-3-yl (A56 as defined in table 56) and B is as defined in each row of Table P.

The compounds according to the invention can be used for controlling or destroying pests such as insects and/or fungi which occur in particular on plants, especially on useful plants and ornamentals in agriculture, in horticulture and in forests, or on organs, such as fruits, flowers, foliage, stalks, tubers, seeds or roots, of such plants, and in some cases even plant organs which are formed at a later point in time remain protected against these pests. The compounds of formula (I) according to the invention are preventively and/or curatively valuable active ingredients in the field of pest control, even at low rates of application, which can be used against pesticide resistant pests such as insects and fungi, which compounds of formula (I) have a very favorable biocidal spectrum and are well tolerated by warm-blooded species, fish and plants. Accordingly, the present invention also makes available a pesticidal composition comprising compounds of the invention, such as formula (I).

It has now been found that the compounds of formula (I) according to the invention have, for practical purposes, a very advantageous spectrum of activities for protecting animals and useful plants against attack and damage by nematodes. Accordingly, the present invention also makes available a nematicidal composition comprising compounds of the invention, such as formula (I).

The compounds of formula (I) are especially useful for the control of nematodes. Thus, in a further aspect, the invention also relates to a method of controlling damage to plant and parts thereof by plant parasitic nematodes (Endoparasitic-, Semiendoparasitic- and Ectoparasitic nematodes), especially plant parasitic nematodes such as root knot nematodes, Meloidogyne hapla, Meloidogyne incognita, Meloidogyne javanica, Meloidogyne arenaria and other Meloidogyne species; cyst-forming nematodes, Globodera rostochiensis and other Globodera species; Heterodera avenae, Heterodera glycines, Heterodera schachtii, Heterodera trifolii, and other Heterodera species; Seed gall nematodes, Anguina species; Stem and foliar nematodes, Aphelenchoides species; Sting nematodes,

Eelonolaimus longicaudatus and other Belonolaimus species; Pine nematodes, Bursaphelenchus xylophilus and other Bursaphelenchus species; Ring nematodes, Criconema species, Criconemella species, Criconemoides species, Mesocriconema species; Stem and bulb nematodes, Ditylenchus destructor, Ditylenchus dipsaci and other Ditylenchus species; Awl nematodes, Dolichodorus species; Spiral nematodes, Heliocotylenchus multicinctus and other Helicotylenchus species; Sheath and sheathoid nematodes, Hemicycliophora species and Hemicriconemoides species; Hirshmanniella species; Lance nematodes, Hoploaimus species; false rootknot nematodes, Nacobbus species;

Needle nematodes, Longidorus elongatus and other Longidorus species; Pin nematodes, Pratylenchus species; Lesion nematodes, Pratylenchus neglectus, Pratylenchus penetrans, Pratylenchus curvitatus, Pratylenchus goodeyi and other Pratylenchus species; Burrowing nematodes, Radopholus similis and other Radopholus species; Reniform nematodes, Rotylenchus robustus, Rotylenchus reniformis and other Rotylenchus species; Scutellonema species; Stubby root nematodes, Trichodorus primitivus and other Trichodorus species, Paratrichodorus species; Stunt nematodes, Tylenchorhynchus claytoni, Tylenchorhynchus dubius and other Tylenchorhynchus species; Citrus nematodes, Tylenchulus species; Dagger nematodes, Xiphinema species; and other plant parasitic nematode species, such as Subanguina spp., Hypsoperine spp., Macroposthonia spp., Melinius spp., Punctodera spp., and Quinisulcius spp..

Particularly, the nematode species Meloidogyne spp., Heterodera spp., Rotylenchus spp. and Pratylenchus spp. can be controlled by compounds of the invention.

Generally, a compound of the present invention is used in the form of a composition (e.g.

formulation) containing a carrier. A compound of the invention and compositions thereof can be used in various forms such as aerosol dispenser, capsule suspension, cold fogging concentrate, dustable powder, emulsifiable concentrate, emulsion oil in water, emulsion water in oil, encapsulated granule, fine granule, flowable concentrate for seed treatment, gas (under pressure), gas generating product, granule, hot fogging concentrate, macrogranule, microgranule, oil dispersible powder, oil miscible flowable concentrate, oil miscible liquid, paste, plant rodlet, powder for dry seed treatment, seed coated with a pesticide, soluble concentrate, soluble powder, solution for seed treatment, suspension concentrate (flowable concentrate), ultra low volume (ulv) liquid, ultra low volume (ulv) suspension, water dispersible granules or tablets, water dispersible powder for slurry treatment, water soluble granules or tablets, water soluble powder for seed treatment and wettable powder.

A formulation typically comprises a liquid or solid carrier and optionally one or more customary formulaton auxiliaries, which may be solid or liquid auxiliaries, for example unepoxidized or epoxidized vegetable oils (for example epoxidized coconut oil, rapeseed oil or soya oil), antifoams, for example silicone oil, preservatives, clays, inorganic compounds, viscosity regulators, surfactant, binders and/or tackifiers. The composition may also further comprise a fertilizer, a micronutrient donor or other preparations which influence the growth of plants as well as comprising a combination containing the compound of the invention with one or more other biologically active agents, such as bactericides, fungicides, nematocides, plant activators, acaricides, and insecticides.

Accordingly, the present invention also makes available a composition comprising a compound of the invention and an agronomicaly carrier and optionally one or more customary formulation auxiliaries.

The compositions are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid compound of the present invention and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the compound of the present invention with the auxiliary (auxiliaries). In the case of solid compounds of the invention, the grinding/milling of the compounds is to ensure specific particle size. These processes for the preparation of the compositions and the use of the compounds of the invention for the preparation of these compositions are also a subject of the invention.

Examples of compositions for use in agriculture are emulsifiable concentrates, suspension concentrates, microemulsions, oil dispersibles, directly sprayable or dilutable solutions, spreadable pastes, dilute emulsions, soluble powders, dispersible powders, wettable powders, dusts, granules or encapsulations in polymeric substances, which comprise - at least - a compound according to the invention and the type of composition is to be selected to suit the intended aims and the prevailing circumstances.

Examples of suitable liquid carriers are unhydrogenated or partially hydrogenated aromatic hydrocarbons, preferably the fractions C ₈ to C ₁₂ of alkylbenzenes, such as xylene mixtures, alkylated naphthalenes or tetrahydronaphthalene, aliphatic or cycloaliphatic hydrocarbons, such as paraffins or cyclohexane, alcohols such as ethanol, propanol or butanol, glycols and their ethers and esters such as propylene glycol, dipropylene glycol ether, ethylene glycol or ethylene glycol monomethyl ether or ethylene glycol monoethyl ether, ketones, such as cyclohexanone, isophorone or diacetone alcohol, strongly polar solvents, such as N-methylpyrrolid-2-one, dimethyl sulfoxide or N,N-dimethylformamide, water, unepoxidized or epoxidized vegetable oils, such as unexpodized or epoxidized rapeseed, castor, coconut or soya oil, and silicone oils. Examples of solid carriers which are used for example for dusts and dispersible powders are, as a rule, ground natural minerals such as calcite, talc, kaolin, montmorillonite or attapulgite. To improve the physical properties, it is also possible to add highly disperse silicas or highly disperse absorbtive polymers. Suitable particulate adsorptive carriers for granules are porous types, such as pumice, brick grit, sepiolite or bentonite, and suitable non-sorptive carrier materials are calcite or sand. In addition, a large number of granulated materials of inorganic or organic nature can be used, in particular dolomite or comminuted plant residues.

Suitable surface-active compounds are, depending on the type of the active ingredient to be formulated, non-ionic, cationic and/or anionic surfactants or surfactant mixtures which have good emulsifying, dispersing and wetting properties. The surfactants mentioned below are only to be considered as examples; a large number of further surfactants which are conventionally used in the art of formulation and suitable according to the invention are described in the relevant literature.

Suitable non-ionic surfactants are, especially, polyglycol ether derivatives of aliphatic or cyc- loaliphatic alcohols, of saturated or unsaturated fatty acids or of alkyl phenols which may contain approximately 3 to approximately 30 glycol ether groups and approximately 8 to approximately 20 carbon atoms in the (cyclo)aliphatic hydrocarbon radical or approximately 6 to approximately 18 carbon atoms in the alkyl moiety of the alkyl phenols. Also suitable are water-soluble polyethylene oxide adducts with polypropylene glycol, ethylenediaminopolypropylene glycol or alkyl polypropylene glycol having 1 to approximately 10 carbon atoms in the alkyl chain and approximately 20 to approximately 250 ethylene glycol ether groups and approximately 10 to approximately 100 propylene glycol ether groups. Normally, the abovementioned compounds contain 1 to approximately 5 ethylene glycol units per propylene glycol unit. Examples which may be mentioned are nonylphenoxypolyethoxyethanol, castor oil polyglycol ether, polypropylene glycol/polyethylene oxide adducts,

tributylphenoxypolyethoxyethanol, polyethylene glycol or octylphenoxypolyethoxyethanol. Also suitable are fatty acid esters of polyoxyethylene sorbitan, such as polyoxyethylene sorbitan trioleate.

The cationic surfactants are, especially, quarternary ammonium salts which generally have at least one alkyl radical of approximately 8 to approximately 22 C atoms as substituents and as further substituents (unhalogenated or halogenated) lower alkyl or hydroxyalkyl or benzyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates. Examples are

stearyltrimethylammonium chloride and benzylbis(2-chloroethyl)ethylammonium bromide.

Examples of suitable anionic surfactants are water-soluble soaps or water-soluble synthetic surface-active compounds. Examples of suitable soaps are the alkali, alkaline earth or (unsubstituted or substituted) ammonium salts of fatty acids having approximately 10 to approximately 22 C atoms, such as the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which are obtainable for example from coconut or tall oil; mention must also be made of the fatty acid methyl taurates. However, synthetic surfactants are used more frequently, in particular fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylaryl sulfonates. As a rule, the fatty sulfonates and fatty sulfates are present as alkali, alkaline earth or (substituted or unsubstituted) ammonium salts and they generally have an alkyl radical of approximately 8 to approximately 22 C atoms, alkyl also to be understood as including the alkyl moiety of acyl radicals; examples which may be mentioned are the sodium or calcium salts of lignosulfonic acid, of the dodecylsulphuric ester or of a fatty alcohol sulfate mixture prepared from natural fatty acids. This group also includes the salts of the sulphuric esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulphonyl groups and a fatty acid radical of approximately 8 to approximately 22 C atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolammonium salts of decylbenzenesulfonic acid, of dibutylnaphthalenesulfonic acid or of a naphthalenesulfonic

acid/formaldehyde condensate. Also possible are, furthermore, suitable phosphates, such as salts of the phosphoric ester of a p-nonylphenol/(4-14)ethylene oxide adduct, or phospholipids.

As a rule, the compositions comprise 0.1 to 99%, especially 0.1 to 95%, of compound according to the present invention and 1 to 99.9%, especially 5 to 99.9%, of at least one solid or liquid carrier, it being possible as a rule for 0 to 25%, especially 0.1 to 20%, of the composition to be surfactants (% in each case meaning percent by weight). Whereas concentrated compositions tend to be preferred for commercial goods, the end consumer as a rule uses dilute compositions which have substantially lower concentrations of active ingredient.

Examples of foliar formulation types for pre-mix compositions are:

GR: Granules

WP: wettable powders

WG : water dispersable granules (powders)

SG: water soluble granules

SL: soluble concentrates

EC: emulsifiable concentrate

EW: emulsions, oil in water

ME: micro-emulsion

SC: aqueous suspension concentrate

CS: aqueous capsule suspension

OD: oil-based suspension concentrate, and

SE: aqueous suspo-emulsion. Whereas, examples of seed treatment formulation types for pre- mix compositions are:

WS: wettable powders for seed treatment slurry

LS: solution for seed treatment

ES: emulsions for seed treatment

FS: suspension concentrate for seed treatment

WG : water dispersible granules, and

CS: aqueous capsule suspension.

Examples of formulation types suitable for tank-mix compositions are solutions, dilute emulsions, suspensions, or a mixture thereof, and dusts. As with the nature of the formulations, the methods of application, such as foliar, drench, spraying, atomizing, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.

The tank-mix compositions are generally prepared by diluting with a solvent (for example, water) the one or more pre-mix compositions containing different pesticides, and optionally further auxiliaries.

Suitable carriers and adjuvants can be solid or liquid and are the substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers.

Generally, a tank-mix formulation for foliar or soil application comprises 0.1 to 20%, especially 0.1 to 15 %, of the desired ingredients, and 99.9 to 80 %, especially 99.9 to 85 %, of a solid or liquid auxiliaries (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 20 %, especially 0.1 to 15 %, based on the tank-mix formulation.

Typically, a pre-mix formulation for foliar application comprises 0.1 to 99.9 %, especially 1 to 95 %, of the desired ingredients, and 99.9 to 0.1 %, especially 99 to 5 %, of a solid or liquid adjuvant (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 50 %, especially 0.5 to 40 %, based on the pre-mix formulation.

Normally, a tank-mix formulation for seed treatment application comprises 0.25 to 80%, especially 1 to 75 %, of the desired ingredients, and 99.75 to 20 %, especially 99 to 25 %, of a solid or liquid auxiliaries (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 40 %, especially 0.5 to 30 %, based on the tank-mix formulation.

Typically, a pre-mix formulation for seed treatment application comprises 0.5 to 99.9 %, especially 1 to 95 %, of the desired ingredients, and 99.5 to 0.1 %, especially 99 to 5 %, of a solid or liquid adjuvant (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 50 %, especially 0.5 to 40 %, based on the pre-mix formulation.

Whereas commercial products will preferably be formulated as concentrates (e.g., pre-mix composition (formulation)), the end user will normally employ dilute formulations (e.g., tank mix composition).

Preferred seed treatment pre-mix formulations are aqueous suspension concentrates. The formulation can be applied to the seeds using conventional treating techniques and machines, such as fluidized bed techniques, the roller mill method, rotostatic seed treaters, and drum coaters. Other methods, such as spouted beds may also be useful. The seeds may be presized before coating. After coating, the seeds are typically dried and then transferred to a sizing machine for sizing. Such procedures are known in the art. The compounds of the present invention are particularly suited for use in soil and seed treatment applications.

In general, the pre-mix compositions of the invention contain 0.5 to 99.9 especially 1 to 95, advantageously 1 to 50, %, by mass of the desired ingredients, and 99.5 to 0.1 , especially 99 to 5, %, by mass of a solid or liquid adjuvant (including, for example, a solvent such as water), where the auxiliaries (or adjuvant) can be a surfactant in an amount of 0 to 50, especially 0.5 to 40, %, by mass based on the mass of the pre-mix formulation. A compound of the formula (I) in a preferred embodiment, independent of any other

embodiments, is in the form of a plant propagation material treating (or protecting) composition, wherein said plant propagation material protecting composition may comprises additionally a colouring agent. The plant propagation material protecting composition or mixture may also comprise at least one polymer from water-soluble and water-dispersible film-forming polymers that improve the adherence of the active ingredients to the treated plant propagation material, which polymer generally has an average molecular weight of at least 10,000 to about 100,000.

Examples of application methods for the compounds of the invention and compositions thereof, that is the methods of controlling pests in the agriculture, are spraying, atomizing, dusting, brushing on, dressing, scattering or pouring - which are to be selected to suit the intended aims of the prevailing circumstances.

One method of application in agriculture is application to the foliage of the plants (foliar application), it being possible to select frequency and rate of application to match the danger of infestation with the pest/fungi in question. Alternatively, the active ingredient can reach the plants via the root system (systemic action), by applying the compound to the locus of the plants, for example by application of a liquid composition of the compound into the soil (by drenching), or by applying a solid form of the compound in the form of granules to the soil (soil application). In the case of paddy rice plants, such granules can be metered into the flooded paddy-field. The application of the compounds of the present invention to the soil is a preferred application method.

Typical rates of application per hectare is generally 1 to 2000 g of active ingredient per hectare, in particular 10 to 1000 g/ha, preferably 10 to 600 g/ha, such as 50 to 300 g/ha.

The compounds of the invention and compositions thereof are also suitable for the protection of plant propagation material, for example seeds, such as fruit, tubers or kernels, or nursery plants, against pests of the abovementioned type. The propagation material can be treated with the compound prior to planting, for example seed can be treated prior to sowing. Alternatively, the compound can be applied to seed kernels (coating), either by soaking the kernels in a liquid composition or by applying a layer of a solid composition. It is also possible to apply the compositions when the propagation material is planted to the site of application, for example into the seed furrow during drilling. These treatment methods for plant propagation material and the plant propagation material thus treated are further subjects of the invention. Typical treatment rates would depend on the plant and pest/fungi to be controlled and are generally between 1 to 200 grams per 100 kg of seeds, preferably between 5 to 150 grams per 100 kg of seeds, such as between 10 to 100 grams per 100 kg of seeds. The application of the compounds of the present invention to seeds is a preferred application method.

The term seed embraces seeds and plant propagules of all kinds including but not limited to true seeds, seed pieces, suckers, corns, bulbs, fruit, tubers, grains, rhizomes, cuttings, cut shoots and the like and means in a preferred embodiment true seeds.

The present invention also comprises seeds coated or treated with or containing a compound of formula (I). The term "coated or treated with and/or containing" generally signifies that the active ingredient is for the most part on the surface of the seed at the time of application, although a greater or lesser part of the ingredient may penetrate into the seed material, depending on the method of application. When the said seed product is (re)planted, it may absorb the active ingredient. In an embodiment, the present invention makes available a plant propagation material adhered thereto with a compound of formula (I). Further, it is hereby made available, a composition comprising a plant propagation material treated with a compound of formula (I).

Seed treatment comprises all suitable seed treatment techniques known in the art, such as seed dressing, seed coating, seed dusting, seed soaking and seed pelleting. The seed treatment application of the compound formula (I), which is a preferred application method, can be carried out by any known methods, such as spraying or by dusting the seeds before sowing or during the sowing/planting of the seeds.

Suitable target plants are, in particular, cereals, such as wheat, barley, rye, oats, rice, maize or sorghum; beet, such as sugar or fodder beet; fruit, for example pomaceous fruit, stone fruit or soft fruit, such as apples, pears, plums, peaches, almonds, cherries or berries, for example strawberries, raspberries or blackberries; leguminous plants, such as beans, lentils, peas or soya; oil plants, such as oilseed rape, mustard, poppies, olives, sunflowers, coconut, castor, cocoa or ground nuts; cucurbits, such as pumpkins, cucumbers or melons; fibre plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruit or tangerines; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes or bell peppers; Lauraceae, such as avocado,

Cinnamonium or camphor; and also tobacco, nuts, coffee, eggplants, sugarcane, tea, pepper, grapevines, hops, the plantain family, latex plants and ornamentals (such as flowers, amd lawn grass or turf).

In an embodiment, the plant is selected from cereals, corn, soybean, rice, sugarcane, vegetables and oil plants.

The term "plant" is to be understood as including also plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as δ-endotoxins, e.g. Cry1 Ab, Cry1 Ac, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1 , Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl- transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

In the context of the present invention there are to be understood by δ-endotoxins, for example CrylAb, CrylAc, Cryl F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1 , Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701 ). Truncated toxins, for example a truncated CrylAb, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G- recognition sequence is inserted into a Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93/07278, WO 95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.

The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. Cryl-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651 .

The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a CrylAb toxin); YieldGard Rootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a CrylAb and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1 Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CrylAc toxin); Bollgard I® (cotton variety that expresses a CrylAc toxin); Bollgard II® (cotton variety that expresses a CrylAc and a Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and a CrylAb toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait) and Protecta®.

Further examples of such transgenic plants are:

1 . Bt1 1 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Osthnia nubilalis and Sesamia nonaghoides) by transgenic expression of a truncated Cry1 Ab toxin. Bt1 1 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

2. Bt176 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Osthnia nubilalis and Sesamia nonaghoides) by transgenic expression of a CrylAb toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

3. MIR604 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.

4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects.

5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/ES/96/02.

6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1 160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1 F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.

7. NK603 x MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 ^χ MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CrylAb toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer.

Compounds of this invention are effective for controlling nematode, insect, acarid pests and/or fungal pathogens of agronomic plants, both growing and harvested, when employed alone, they may also be used in combination with other biological active agents used in agriculture, such as one or more nematicides, insecticides, acaricides, fungicides, bactericides, plant activator, molluscicide, and pheromones (whether chemical or biological). Mixing the compounds of the invention or the compositions thereof in the use form as pesticides with other pesticides frequently results in a broader pesticidal spectrum of action. For example, the formula (I) compounds of this invention may be used effectively in conjunction or combination with pyrethroids, neonicotinoids, macrolides, diamides, phosphates, carbamates, cyclodienes, formamidines, phenol tin compounds, chlorinated

hydrocarbons, benzoylphenyl ureas, pyrroles and the like. The activity of the compositions according to the invention can be broadened considerably, and adapted to prevailing circumstances, by adding, for example, one or more insecticidally, acaricidally, nematicidally and/or fungicidally active agents. The combinations compounds of formula (I) with other insecticidally, acaricidally, nematicidally and/or fungicidally active agents may also have further surprising advantages which can also be described, in a wider sense, as synergistic activity. For example, better tolerance by plants, reduced phytotoxicity, pests or fungi can be controlled in their different development stages or better behaviour during their production, for example during grinding or mixing, during their storage or during their use.

The following list of pesticides together with which the compounds according to the invention can be used, is intended to illustrate the possible combinations by way of example.

The following combination of the compounds of formula (I) with another active compounds are preferred (the abbreviation "TX" means a compound of the formula (I), preferably a compound selected from the compounds described in Tables 1 to 1 12 shown above, more preferably a compound selected from the compounds shown in Tables 1 13 to 1 14, even more preferably from a compound selected from 1 14-3, 1 14-7, 1 14-1 1 , 1 14-13, 1 14-17, 1 14-18, 1 14-20, 1 14-21 , 1 14-22, 1 14-23, 1 14-25, 1 14-35, 1 14-26, 1 14-42, 1 14-44, 1 14-45, 1 14-50, 1 15-1 ):

an adjuvant selected from the group of substances consisting of petroleum oils (alternative name) (628) + TX,

an acaricide selected from the group of substances consisting of 1 ,1 -bis(4-chlorophenyl)-2- ethoxyethanol (lUPAC name) (910) + TX, 2,4-dichlorophenyl benzenesulfonate (lUPAC/Chemical

Abstracts name) (1059) + TX, 2-fluoro-A/-methyl-A/-1 -naphthylacetamide (lUPAC name) (1295) + TX, 4-chlorophenyl phenyl sulfone (lUPAC name) (981 ) + TX, abamectin (1 ) + TX, acequinocyl (3) + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, alpha- cypermethrin (202) + TX, amidithion (870) + TX, amidoflumet [CCN] + TX, amidothioate (872) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, aramite (881 ) + TX, arsenous oxide (882) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azobenzene (lUPAC name) (888) + TX, azocyclotin (46) + TX, azothoate (889) + TX, benomyl (62) + TX, benoxafos (alternative name) [CCN] + TX, benzoximate (71 ) + TX, benzyl benzoate (lUPAC name) [CCN] + TX, bifenazate (74) + TX, bifenthrin (76) + TX, binapacryl (907) + TX, brofenvalerate (alternative name) + TX, bromocyclen (918) + TX, bromophos (920) + TX, bromophos-ethyl (921 ) + TX, bromopropylate (94) + TX, buprofezin (99) + TX, butocarboxim (103) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, calcium polysulfide (lUPAC name) (1 1 1 ) + TX, camphechlor (941 ) + TX, carbanolate (943) + TX, carbaryl (1 15) + TX, carbofuran (1 18) + TX, carbophenothion (947) + TX, CGA 50'439 (development code) (125) + TX, chinomethionat (126) + TX, chlorbenside (959) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorfenapyr (130) + TX, chlorfenethol (968) + TX, chlorfenson (970) + TX, chlorfensulphide (971 ) + TX, chlorfenvinphos (131 ) + TX, chlorobenzilate (975) + TX, chloromebuform (977) + TX, chloromethiuron (978) + TX, chloropropylate (995) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, clofentezine (158) + TX, closantel (alternative name) [CCN] + TX, coumaphos (174) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, cufraneb (1013) + TX, cyanthoate (1020) + TX, cyflumetofen (CAS Reg. No.: 400882-07-7) + TX, cyhalothrin (196) + TX, cyhexatin (199) + TX, cypermethrin (201 ) + TX, DCPM (1032) + TX, DDT (219) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-0 (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthiuron (226) + TX, dialifos (1042) + TX, diazinon (227) + TX, dichlofluanid (230) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicofol (242) + TX, dicrotophos (243) + TX, dienochlor (1071 ) + TX, dimefox (1081 ) + TX, dimethoate (262) + TX, dinactin (alternative name) (653) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinobuton (269) + TX, dinocap (270) + TX, dinocap-4 [CCN] + TX, dinocap-6 [CCN] + TX, dinocton (1090) + TX, dinopenton (1092) + TX, dinosulfon (1097) + TX, dinoterbon (1098) + TX, dioxathion (1 102) + TX, diphenyl sulfone (lUPAC name) (1 103) + TX, disulfiram (alternative name) [CCN] + TX, disulfoton (278) + TX, DNOC (282) + TX, dofenapyn (1 1 13) + TX, doramectin (alternative name) [CCN] + TX, endosulfan (294) + TX, endothion (1 121 ) + TX, EPN (297) + TX, eprinomectin (alternative name) [CCN] + TX, ethion (309) + TX, ethoate-methyl (1 134) + TX, etoxazole (320) + TX, etrimfos (1 142) + TX, fenazaflor (1 147) + TX, fenazaquin (328) + TX, fenbutatin oxide (330) + TX, fenothiocarb (337) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fenpyroximate (345) + TX, fenson (1 157) + TX, fentrifanil (1 161 ) + TX, fenvalerate (349) + TX, fipronil (354) + TX, fluacrypyrim (360) + TX, fluazuron (1 166) + TX, flubenzimine (1 167) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1 169) + TX, flufenoxuron (370) + TX, flumethrin (372) + TX, fluorbenside (1 174) + TX, fluvalinate (1 184) + TX, FMC 1 137 (development code) (1 185) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1 192) + TX, formparanate (1 193) + TX, gamma-HCH (430) + TX, glyodin (1205) + TX, halfenprox (424) + TX, heptenophos (432) + TX, hexadecyl cyclopropanecarboxylate (lUPAC/Chemical Abstracts name) (1216) + TX, hexythiazox (441 ) + TX, iodomethane (lUPAC name) (542) + TX, isocarbophos

(alternative name) (473) + TX, isopropyl 0-(methoxyaminothiophosphoryl)salicylate (lUPAC name) (473) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, lindane (430) + TX, lufenuron (490) + TX, malathion (492) + TX, malonoben (1254) + TX, mecarbam (502) + TX, mephosfolan (1261 ) + TX, mesulfen (alternative name) [CCN] + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methidathion (529) + TX, methiocarb (530) + TX, methomyl (531 ) + TX, methyl bromide (537) + TX, metolcarb (550) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, monocrotophos (561 ) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naled (567) + TX, NC-184 (compound code) + TX, NC-512 (compound code) + TX, nifluridide (1309) + TX, nikkomycins (alternative name) [CCN] + TX, nitrilacarb (1313) + TX, nitrilacarb 1 :1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, parathion (615) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, phenkapton (1330) + TX, phenthoate (631 ) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosphamidon (639) + TX, phoxim (642) + TX, pirimiphos-methyl (652) + TX, polychloroterpenes (traditional name) (1347) + TX, polynactins (alternative name) (653) + TX, proclonol (1350) + TX, profenofos (662) + TX, promacyl (1354) + TX, propargite (671 ) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothoate (1362) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridaphenthion (701 ) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, quinalphos (71 1 ) + TX, quintiofos (1381 ) + TX, R-1492 (development code) (1382) + TX, RA-17 (development code) (1395) + TX, rotenone (722) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, sophamide (1402) + TX, spirodiclofen (738) + TX, spiromesifen (739) + TX, SSI-121 (development code) (1404) + TX, sulfiram (alternative name) [CCN] + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulphur (754) + TX, SZI-121 (development code) (757) + TX, tau-fluvalinate (398) + TX, tebufenpyrad (763) + TX, TEPP (1417) + TX, terbam (alternative name) + TX, tetrachlorvinphos (777) + TX, tetradifon (786) + TX, tetranactin (alternative name) (653) + TX, tetrasul (1425) + TX, thiafenox (alternative name) + TX, thiocarboxime (1431 ) + TX, thiofanox (800) + TX, thiometon (801 ) + TX, thioquinox (1436) + TX, thuringiensin (alternative name) [CCN] + TX, triamiphos (1441 ) + TX, triarathene (1443) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trifenofos (1455) + TX, trinactin (alternative name) (653) + TX, vamidothion (847) + TX, vaniliprole [CCN] and YI-5302 (compound code) + TX,

an algicide selected from the group of substances consisting of bethoxazin [CCN] + TX, copper dioctanoate (lUPAC name) (170) + TX, copper sulfate (172) + TX, cybutryne [CCN] + TX, dichlone (1052) + TX, dichlorophen (232) + TX, endothal (295) + TX, fentin (347) + TX, hydrated lime [CCN] + TX, nabam (566) + TX, quinoclamine (714) + TX, quinonamid (1379) + TX, simazine (730) + TX, triphenyltin acetate (lUPAC name) (347) and triphenyltin hydroxide (lUPAC name) (347) + TX,

an anthelmintic selected from the group of substances consisting of abamectin (1 ) + TX, crufomate (101 1 ) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, eprinomectin (alternative name) [CCN] + TX, ivermectin (alternative name) [CCN] + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, piperazine [CCN] + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) and thiophanate (1435) + TX,

an avicide selected from the group of substances consisting of chloralose (127) + TX, endrin (1 122) + TX, fenthion (346) + TX, pyridin-4-amine (lUPAC name) (23) and strychnine (745) + TX, a bactericide selected from the group of substances consisting of 1 -hydroxy-1 H-pyridine-2- thione (lUPAC name) (1222) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (lUPAC name) (748) + TX, 8-hydroxyquinoline sulfate (446) + TX, bronopol (97) + TX, copper dioctanoate (lUPAC name) (170) + TX, copper hydroxide (lUPAC name) (169) + TX, cresol [CCN] + TX, dichlorophen (232) + TX, dipyrithione (1 105) + TX, dodicin (1 1 12) + TX, fenaminosulf (1 144) + TX, formaldehyde (404) + TX, hydrargaphen (alternative name) [CCN] + TX, kasugamycin (495) + TX, kasugamycin hydrochloride hydrate (483) + TX, nickel bis(dimethyldithiocarbamate) (lUPAC name) (1308) + TX, nitrapyrin (580) + TX, octhilinone (590) + TX, oxolinic acid (606) + TX, oxytetracycline (61 1 ) + TX, potassium

hydroxyquinoline sulfate (446) + TX, probenazole (658) + TX, streptomycin (744) + TX, streptomycin sesquisulfate (744) + TX, tecloftalam (766) + TX, and thiomersal (alternative name) [CCN] + TX,

a biological agent selected from the group of substances consisting of Adoxophyes orana GV

(alternative name) (12) + TX, Agrobacterium radiobacter (alternative name) (13) + TX, Amblyseius spp. (alternative name) (19) + TX, Anagrapha falcifera NPV (alternative name) (28) + TX, Anagrus atomus (alternative name) (29) + TX, Aphelinus abdominalis (alternative name) (33) + TX, Aphidius colemani (alternative name) (34) + TX, Aphidoletes aphidimyza (alternative name) (35) + TX, Autographa californica NPV (alternative name) (38) + TX, Bacillus firmus (alternative name) (48) + TX, Bacillus sphaericus Neide (scientific name) (49) + TX, Bacillus thuringiensis Berliner (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. aizawai (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. israelensis (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. japonensis (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. kurstaki (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. tenebrionis (scientific name) (51 ) + TX, Beauveria bassiana (alternative name) (53) + TX, Beauveria brongniartii (alternative name) (54) + TX, Chrysoperla carnea (alternative name) (151 ) + TX,

Cryptolaemus montrouzieri (alternative name) (178) + TX, Cydia pomonella GV (alternative name) (191 ) + TX, Dacnusa sibirica (alternative name) (212) + TX, Diglyphus isaea (alternative name) (254) + TX, Encarsia formosa (scientific name) (293) + TX, Eretmocerus eremicus (alternative name) (300) + TX, Helicoverpa zea NPV (alternative name) (431 ) + TX, Heterorhabditis bacteriophora and H. megidis (alternative name) (433) + TX, Hippodamia convergens (alternative name) (442) + TX, Leptomastix dactylopii (alternative name) (488) + TX, Macrolophus caliginosus (alternative name) (491 ) + TX, Mamestra brassicae NPV (alternative name) (494) + TX, Metaphycus helvolus (alternative name) (522) + TX, Metarhizium anisopliae var. acridum (scientific name) (523) + TX, Metarhizium anisopliae var. anisopliae (scientific name) (523) + TX, Neodiprion sertifer NPV and N. lecontei NPV (alternative name) (575) + TX, Orius spp. (alternative name) (596) + TX, Paecilomyces fumosoroseus (alternative name) (613) + TX, Pasteuria penetrans + TX, Pasteuria thornei + TX, Pasteuria nishizawae + TX, Pasteuria ramosa + TX, Phytoseiulus persimilis (alternative name) (644) + TX, Spodoptera exigua multicapsid nuclear polyhedrosis virus (scientific name) (741 ) + TX, Steinernema bibionis (alternative name) (742) + TX, Steinernema carpocapsae (alternative name) (742) + TX, Steinernema feltiae (alternative name) (742) + TX, Steinernema glaseri (alternative name) (742) + TX, Steinernema riobrave (alternative name) (742) + TX, Steinernema riobravis (alternative name) (742) + TX,

Steinernema scapterisci (alternative name) (742) + TX, Steinernema spp. (alternative name) (742) + TX, Trichogramma spp. (alternative name) (826) + TX, Typhlodromus occidentalis (alternative name) (844) and Verticillium lecanii (alternative name) (848) + TX,

a soil sterilant selected from the group of substances consisting of iodomethane (lUPAC name) (542) and methyl bromide (537) + TX,

a chemosterilant selected from the group of substances consisting of apholate [CCN] + TX, bisazir (alternative name) [CCN] + TX, busulfan (alternative name) [CCN] + TX, diflubenzuron (250) + TX, dimatif (alternative name) [CCN] + TX, hemel [CCN] + TX, hempa [CCN] + TX, metepa [CCN] + TX, methiotepa [CCN] + TX, methyl apholate [CCN] + TX, morzid [CCN] + TX, penfluron (alternative name) [CCN] + TX, tepa [CCN] + TX, thiohempa (alternative name) [CCN] + TX, thiotepa (alternative name) [CCN] + TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN] + TX, an insect pheromone selected from the group of substances consisting of (E)-dec-5-en-1 -yl acetate with (E)-dec-5-en-1 -ol (lUPAC name) (222) + TX, (E)-tridec-4-en-1 -yl acetate (lUPAC name) (829) + TX, (E)-6-methylhept-2-en-4-ol (lUPAC name) (541 ) + TX, (E,Z)-tetradeca-4,10-dien-1 -yl acetate (lUPAC name) (779) + TX, (Z)-dodec-7-en-1 -yl acetate (lUPAC name) (285) + TX, (Z)- hexadec-1 1 -enal (lUPAC name) (436) + TX, (Z)-hexadec-l 1 -en-1 -yl acetate (lUPAC name) (437) + TX, (Z)-hexadec-13-en-1 1 -yn-1 -yl acetate (lUPAC name) (438) + TX, (Z)-icos-13-en-10-one (lUPAC name) (448) + TX, (Z)-tetradec-7-en-1 -al (lUPAC name) (782) + TX, fZ)-tetradec-9-en-1 -ol (lUPAC name) (783) + TX, (Z)-tetradec-9-en-1 -yl acetate (lUPAC name) (784) + TX, (7E,9Z)-dodeca-7,9-dien- 1 -yl acetate (lUPAC name) (283) + TX, (9Z,1 1 E)-tetradeca-9,1 1 -dien-1 -yl acetate (lUPAC name) (780) + TX, (9Z, 12E)-tetradeca-9,12-dien-1 -yl acetate (lUPAC name) (781 ) + TX, 14-methyloctadec-1 -ene (lUPAC name) (545) + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (lUPAC name) (544) + TX, alpha-multistriatin (alternative name) [CCN] + TX, brevicomin (alternative name) [CCN] + TX, codlelure (alternative name) [CCN] + TX, codlemone (alternative name) (167) + TX, cuelure (alternative name) (179) + TX, disparlure (277) + TX, dodec-8-en-1 -yl acetate (lUPAC name) (286) + TX, dodec-9-en-1 -yl acetate (lUPAC name) (287) + TX, dodeca-8 + TX, 10-dien-1 -yl acetate (lUPAC name) (284) + TX, dominicalure (alternative name) [CCN] + TX, ethyl 4-methyloctanoate (lUPAC name) (317) + TX, eugenol (alternative name) [CCN] + TX, frontalin (alternative name) [CCN] + TX, gossyplure

(alternative name) (420) + TX, grandlure (421 ) + TX, grandlure I (alternative name) (421 ) + TX, grandlure II (alternative name) (421 ) + TX, grandlure III (alternative name) (421 ) + TX, grandlure IV (alternative name) (421 ) + TX, hexalure [CCN] + TX, ipsdienol (alternative name) [CCN] + TX, ipsenol (alternative name) [CCN] + TX, japonilure (alternative name) (481 ) + TX, lineatin (alternative name) [CCN] + TX, litlure (alternative name) [CCN] + TX, looplure (alternative name) [CCN] + TX, medlure [CCN] + TX, megatomoic acid (alternative name) [CCN] + TX, methyl eugenol (alternative name) (540) + TX, muscalure (563) + TX, octadeca-2,13-dien-1 -yl acetate (lUPAC name) (588) + TX, octadeca- 3,13-dien-1 -yl acetate (lUPAC name) (589) + TX, orfralure (alternative name) [CCN] + TX, oryctalure (alternative name) (317) + TX, ostramone (alternative name) [CCN] + TX, siglure [CCN] + TX, sordidin (alternative name) (736) + TX, sulcatol (alternative name) [CCN] + TX, tetradec-1 1 -en-1 -yl acetate (lUPAC name) (785) + TX, trimedlure (839) + TX, trimedlure A (alternative name) (839) + TX, trimedlure B-i (alternative name) (839) + TX, trimedlure B ₂ (alternative name) (839) + TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN] + TX,

an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol

(lUPAC name) (591 ) + TX, butopyronoxyl (933) + TX, butoxy(polypropylene glycol) (936) + TX, dibutyl adipate (lUPAC name) (1046) + TX, dibutyl phthalate (1047) + TX, dibutyl succinate (lUPAC name) (1048) + TX, diethyltoluamide [CCN] + TX, dimethyl carbate [CCN] + TX, dimethyl phthalate [CCN] + TX, ethyl hexanediol (1 137) + TX, hexamide [CCN] + TX, methoquin-butyl (1276) + TX,

methylneodecanamide [CCN] + TX, oxamate [CCN] and picaridin [CCN] + TX,

an insecticide selected from the group of substances consisting of 1 -dichloro-1 -nitroethane (lUPAC/Chemical Abstracts name) (1058) + TX, 1 ,1 -dichloro-2,2-bis(4-ethylphenyl)ethane (lUPAC name) (1056), + TX, 1 ,2-dichloropropane (lUPAC/Chemical Abstracts name) (1062) + TX, 1 ,2- dichloropropane with 1 ,3-dichloropropene (lUPAC name) (1063) + TX, 1 -bromo-2-chloroethane (lUPAC/Chemical Abstracts name) (916) + TX, 2,2,2-trichloro-1 -(3,4-dichlorophenyl)ethyl acetate (lUPAC name) (1451 ) + TX, 2,2-dichlorovinyl 2-ethylsulphinylethyl methyl phosphate (lUPAC name) (1066) + TX, 2-(1 ,3-dithiolan-2-yl)phenyl dimethylcarbamate (lUPAC/ Chemical Abstracts name) (1 109) + TX, 2-(2-butoxyethoxy)ethyl thiocyanate (lUPAC/Chemical Abstracts name) (935) + TX, 2- (4,5-dimethyl-1 ,3-dioxolan-2-yl)phenyl methylcarbamate (lUPAC/ Chemical Abstracts name) (1084) + TX, 2-(4-chloro-3,5-xylyloxy)ethanol (lUPAC name) (986) + TX, 2-chlorovinyl diethyl phosphate (lUPAC name) (984) + TX, 2-imidazolidone (lUPAC name) (1225) + TX, 2-isovalerylindan-1 ,3-dione (lUPAC name) (1246) + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate (lUPAC name) (1284) + TX, 2-thiocyanatoethyl laurate (lUPAC name) (1433) + TX, 3-bromo-1 -chloroprop-1 -ene (lUPAC name) (917) + TX, 3-methyl-1 -phenylpyrazol-5-yl dimethylcarbamate (lUPAC name) (1283) + TX, 4- methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate (lUPAC name) (1285) + TX, 5,5-dimethyl-3- oxocyclohex-1 -enyl dimethylcarbamate (lUPAC name) (1085) + TX, abamectin (1 ) + TX, acephate (2) + TX, acetamiprid (4) + TX, acethion (alternative name) [CCN] + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, acrylonitrile (lUPAC name) (861 ) + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, aldrin (864) + TX, allethrin (17) + TX, allosamidin (alternative name) [CCN] + TX, allyxycarb (866) + TX, alpha-cypermethrin (202) + TX, alpha-ecdysone (alternative name) [CCN] + TX, aluminium phosphide (640) + TX, amidithion (870) + TX, amidothioate (872) + TX, aminocarb (873) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, anabasine (877) + TX, athidathion (883) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azadirachtin (alternative name) (41 ) + TX, azamethiphos (42) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azothoate (889) + TX, Bacillus thuhngiensis delta endotoxins (alternative name) (52) + TX, barium hexafluorosilicate (alternative name) [CCN] + TX, barium polysulfide

(lUPAC/Chemical Abstracts name) (892) + TX, barthrin [CCN] + TX, Bayer 22/190 (development code) (893) + TX, Bayer 22408 (development code) (894) + TX, bendiocarb (58) + TX, benfuracarb (60) + TX, bensultap (66) + TX, beta-cyfluthrin (194) + TX, beta-cypermethrin (203) + TX, bifenthrin (76) + TX, bioallethrin (78) + TX, bioallethrin S-cyclopentenyl isomer (alternative name) (79) + TX, bioethanomethrin [CCN] + TX, biopermethrin (908) + TX, bioresmethrin (80) + TX, bis(2-chloroethyl) ether (lUPAC name) (909) + TX, bistrifluron (83) + TX, borax (86) + TX, brofenvalerate (alternative name) + TX, bromfenvinfos (914) + TX, bromocyclen (918) + TX, bromo-DDT (alternative name)

[CCN] + TX, bromophos (920) + TX, bromophos-ethyl (921 ) + TX, bufencarb (924) + TX, buprofezin (99) + TX, butacarb (926) + TX, butathiofos (927) + TX, butocarboxim (103) + TX, butonate (932) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, calcium arsenate [CCN] + TX, calcium cyanide (444) + TX, calcium polysulfide (lUPAC name) (1 1 1 ) + TX, camphechlor (941 ) + TX, carbanolate (943) + TX, carbaryl (1 15) + TX, carbofuran (1 18) + TX, carbon disulfide (lUPAC/Chemical Abstracts name) (945) + TX, carbon tetrachloride (lUPAC name) (946) + TX, carbophenothion (947) + TX, carbosulfan (1 19) + TX, cartap (123) + TX, cartap hydrochloride (123) + TX, cevadine (alternative name) (725) + TX, chlorbicyclen (960) + TX, chlordane (128) + TX, chlordecone (963) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorethoxyfos (129) + TX, chlorfenapyr (130) + TX, chlorfenvinphos (131 ) + TX, chlorfluazuron (132) + TX, chlormephos (136) + TX, chloroform [CCN] + TX, chloropicrin (141 ) + TX, chlorphoxim (989) + TX, chlorprazophos (990) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, chromafenozide (150) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, cis-resmethrin (alternative name) + TX, cismethrin (80) + TX, clocythrin

(alternative name) + TX, cloethocarb (999) + TX, closantel (alternative name) [CCN] + TX, clothianidin (165) + TX, copper acetoarsenite [CCN] + TX, copper arsenate [CCN] + TX, copper oleate [CCN] + TX, coumaphos (174) + TX, coumithoate (1006) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, crufomate (101 1 ) + TX, cryolite (alternative name) (177) + TX, CS 708 (development code) (1012) + TX, cyanofenphos (1019) + TX, cyanophos (184) + TX, cyanthoate

(1020) + TX, cyclethrin [CCN] + TX, cycloprothrin (188) + TX, cyfluthrin (193) + TX, cyhalothrin (196) + TX, cypermethrin (201 ) + TX, cyphenothrin (206) + TX, cyromazine (209) + TX, cythioate (alternative name) [CCN] + TX, d-limonene (alternative name) [CCN] + TX, d-tetramethrin (alternative name) (788) + TX, DAEP (1031 ) + TX, dazomet (216) + TX, DDT (219) + TX, decarbofuran (1034) + TX, deltamethrin (223) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-0 (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthiuron (226) + TX, dialifos (1042) + TX, diamidafos (1044) + TX, diazinon (227) + TX, dicapthon (1050) + TX, dichlofenthion (1051 ) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicresyl (alternative name) [CCN] + TX, dicrotophos (243) + TX, dicyclanil (244) + TX, dieldrin

(1070) + TX, diethyl 5-methylpyrazol-3-yl phosphate (lUPAC name) (1076) + TX, diflubenzuron (250) + TX, dilor (alternative name) [CCN] + TX, dimefluthrin [CCN] + TX, dimefox (1081 ) + TX, dimetan

(1085) + TX, dimethoate (262) + TX, dimethrin (1083) + TX, dimethylvinphos (265) + TX, dimetilan

(1086) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinoprop (1093) + TX, dinosam (1094) + TX, dinoseb (1095) + TX, dinotefuran (271 ) + TX, diofenolan (1099) + TX, dioxabenzofos (1 100) + TX, dioxacarb (1 101 ) + TX, dioxathion (1 102) + TX, disulfoton (278) + TX, dithicrofos (1 108) + TX, DNOC (282) + TX, doramectin (alternative name) [CCN] + TX, DSP (1 1 15) + TX, ecdysterone (alternative name) [CCN] + TX, El 1642 (development code) (1 1 18) + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, EMPC (1 120) + TX, empenthrin (292) + TX, endosulfan (294) + TX, endothion (1 121 ) + TX, endrin (1 122) + TX, EPBP (1 123) + TX, EPN (297) + TX, epofenonane (1 124) + TX, eprinomectin (alternative name) [CCN] + TX, esfenvalerate (302) + TX, etaphos (alternative name) [CCN] + TX, ethiofencarb (308) + TX, ethion (309) + TX, ethiprole (310) + TX, ethoate-methyl (1 134) + TX, ethoprophos (312) + TX, ethyl formate (lUPAC name) [CCN] + TX, ethyl-DDD (alternative name) (1056) + TX, ethylene dibromide (316) + TX, ethylene dichloride (chemical name) (1 136) + TX, ethylene oxide [CCN] + TX, etofenprox (319) + TX, etrimfos (1 142) + TX, EXD (1 143) + TX, famphur (323) + TX, fenamiphos (326) + TX, fenazaflor (1 147) + TX, fenchlorphos (1 148) + TX, fenethacarb (1 149) + TX, fenfluthrin (1 150) + TX, fenitrothion (335) + TX, fenobucarb (336) + TX, fenoxacrim (1 153) + TX, fenoxycarb (340) + TX, fenpirithrin (1 155) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fensulfothion (1 158) + TX, fenthion (346) + TX, fenthion-ethyl [CCN] + TX, fenvalerate (349) + TX, fipronil (354) + TX, flonicamid (358) + TX, flubendiamide (CAS. Reg. No.: 272451 -65-7) + TX, flucofuron (1 168) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1 169) + TX, flufenerim [CCN] + TX, flufenoxuron (370) + TX, flufenprox (1 171 ) + TX, flumethrin (372) + TX, fluvalinate (1 184) + TX, FMC 1 137 (development code) (1 185) + TX, fonofos (1 191 ) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1 192) + TX, formparanate (1 193) + TX, fosmethilan (1 194) + TX, fospirate (1 195) + TX, fosthiazate (408) + TX, fosthietan (1 196) + TX, furathiocarb (412) + TX, furethrin (1200) + TX, gamma-cyhalothrin (197) + TX, gamma-HCH (430) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, GY-81 (development code) (423) + TX, halfenprox (424) + TX, halofenozide (425) + TX, HCH (430) + TX, HEOD (1070) + TX, heptachlor (121 1 ) + TX, heptenophos (432) + TX, heterophos [CCN] + TX, hexaflumuron (439) + TX, HHDN (864) + TX, hydramethylnon (443) + TX, hydrogen cyanide (444) + TX, hydroprene (445) + TX, hyquincarb (1223) + TX, imidacloprid (458) + TX, imiprothrin (460) + TX, indoxacarb (465) + TX, iodomethane (lUPAC name) (542) + TX, IPSP (1229) + TX, isazofos (1231 ) + TX, isobenzan (1232) + TX, isocarbophos (alternative name) (473) + TX, isodrin (1235) + TX, isofenphos (1236) + TX, isolane (1237) + TX, isoprocarb (472) + TX, isopropyl 0-(methoxyaminothiophosphoryl)salicylate (lUPAC name) (473) + TX, isoprothiolane (474) + TX, isothioate (1244) + TX, isoxathion (480) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, juvenile hormone I (alternative name) [CCN] + TX, juvenile hormone II (alternative name) [CCN] + TX, juvenile hormone III (alternative name) [CCN] + TX, kelevan (1249) + TX, kinoprene (484) + TX, lambda-cyhalothrin (198) + TX, lead arsenate [CCN] + TX, lepimectin (CCN) + TX, leptophos (1250) + TX, lindane (430) + TX, lirimfos (1251 ) + TX, lufenuron (490) + TX, lythidathion (1253) + TX, m- cumenyl methylcarbamate (lUPAC name) (1014) + TX, magnesium phosphide (lUPAC name) (640) + TX, malathion (492) + TX, malonoben (1254) + TX, mazidox (1255) + TX, mecarbam (502) + TX, mecarphon (1258) + TX, menazon (1260) + TX, mephosfolan (1261 ) + TX, mercurous chloride (513) + TX, mesulfenfos (1263) + TX, metaflumizone (CCN) + TX, metam (519) + TX, metam-potassium

(alternative name) (519) + TX, metam-sodium (519) + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methanesulphonyl fluoride (lUPAC/Chemical Abstracts name) (1268) + TX, methidathion (529) + TX, methiocarb (530) + TX, methocrotophos (1273) + TX, methomyl (531 ) + TX, methoprene (532) + TX, methoquin-butyl (1276) + TX, methothrin (alternative name) (533) + TX, methoxychlor (534) + TX, methoxyfenozide (535) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, methylchloroform (alternative name) [CCN] + TX, methylene chloride [CCN] + TX, metofluthrin [CCN] + TX, metolcarb (550) + TX, metoxadiazone (1288) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, mirex (1294) + TX, monocrotophos (561 ) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naftalofos (alternative name) [CCN] + TX, naled (567) + TX, naphthalene (lUPAC/Chemical Abstracts name) (1303) + TX, NC-170 (development code) (1306) + TX, NC-184 (compound code) + TX, nicotine (578) + TX, nicotine sulfate (578) + TX, nifluridide (1309) + TX, nitenpyram (579) + TX, nithiazine (131 1 ) + TX, nitrilacarb (1313) + TX, nitrilacarb 1 :1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, nornicotine (traditional name) (1319) + TX, novaluron (585) + TX, noviflumuron (586) + TX, 0-5- dichloro-4-iodophenyl O-ethyl ethylphosphonothioate (lUPAC name) (1057) + TX, 0, 0-diethyl 0-4- methyl-2-oxo-2H-chromen-7-yl phosphorothioate (lUPAC name) (1074) + TX, Ο, Ο-diethyl O-6-methyl- 2-propylpyrimidin-4-yl phosphorothioate (lUPAC name) (1075) + TX, O, Ο, Ο', O'-tetrapropyl dithiopyrophosphate (lUPAC name) (1424) + TX, oleic acid (lUPAC name) (593) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydemeton-methyl (609) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, para-dichlorobenzene [CCN] + TX, parathion (615) + TX, parathion-methyl (616) + TX, penfluron (alternative name) [CCN] + TX, pentachlorophenol (623) + TX, pentachlorophenyl laurate (lUPAC name) (623) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, PH 60-38 (development code) (1328) + TX, phenkapton (1330) + TX, phenothrin (630) + TX, phenthoate (631 ) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosnichlor (1339) + TX, phosphamidon (639) + TX, phosphine (lUPAC name) (640) + TX, phoxim (642) + TX, phoxim-methyl (1340) + TX, pirimetaphos (1344) + TX, pirimicarb (651 ) + TX, pirimiphos-ethyl (1345) + TX, pirimiphos-methyl (652) + TX,

polychlorodicyclopentadiene isomers (lUPAC name) (1346) + TX, polychloroterpenes (traditional name) (1347) + TX, potassium arsenite [CCN] + TX, potassium thiocyanate [CCN] + TX, prallethrin (655) + TX, precocene I (alternative name) [CCN] + TX, precocene II (alternative name) [CCN] + TX, precocene III (alternative name) [CCN] + TX, primidophos (1349) + TX, profenofos (662) + TX, profluthrin [CCN] + TX, promacyl (1354) + TX, promecarb (1355) + TX, propaphos (1356) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothiofos (686) + TX, prothoate (1362) + TX, protrifenbute [CCN] + TX, pymetrozine (688) + TX, pyraclofos (689) + TX, pyrazophos (693) + TX, pyresmethrin (1367) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridalyl (700) + TX, pyridaphenthion (701 ) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, pyriproxyfen (708) + TX, quassia (alternative name) [CCN] + TX, quinalphos (71 1 ) + TX, quinalphos-methyl (1376) + TX, quinothion (1380) + TX, quintiofos (1381 ) + TX, R-1492 (development code) (1382) + TX, rafoxanide (alternative name) [CCN] + TX, resmethrin (719) + TX, rotenone (722) + TX, RU 15525 (development code) (723) + TX, RU 25475 (development code) (1386) + TX, ryania (alternative name) (1387) + TX, ryanodine (traditional name) (1387) + TX, sabadilla (alternative name) (725) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, SI-0205

(compound code) + TX, SI-0404 (compound code) + TX, SI-0405 (compound code) + TX, silafluofen (728) + TX, SN 72129 (development code) (1397) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoride (lUPAC/Chemical Abstracts name) (1399) + TX, sodium hexafluorosilicate (1400) + TX, sodium pentachlorophenoxide (623) + TX, sodium selenate (lUPAC name) (1401 ) + TX, sodium thiocyanate [CCN] + TX, sophamide (1402) + TX, spinosad (737) + TX, spiromesifen (739) + TX, spirotetrmat (CCN) + TX, sulcofuron (746) + TX, sulcofuron-sodium (746) + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulphuryl fluoride (756) + TX, sulprofos (1408) + TX, tar oils (alternative name) (758) + TX, tau-fluvalinate (398) + TX, tazimcarb (1412) + TX, TDE (1414) + TX, tebufenozide (762) + TX, tebufenpyrad (763) + TX, tebupirimfos (764) + TX, teflubenzuron (768) + TX, tefluthrin (769) + TX, temephos (770) + TX, TEPP (1417) + TX, terallethrin (1418) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachloroethane [CCN] + TX, tetrachlorvinphos (777) + TX, tetramethrin (787) + TX, theta-cypermethrin (204) + TX, thiacloprid (791 ) + TX, thiafenox (alternative name) + TX, thiamethoxam (792) + TX, thicrofos (1428) + TX, thiocarboxime (1431 ) + TX, thiocyclam (798) + TX, thiocyclam hydrogen oxalate (798) + TX, thiodicarb (799) + TX, thiofanox (800) + TX, thiometon (801 ) + TX, thionazin (1434) + TX, thiosultap (803) + TX, thiosultap-sodium (803) + TX, thuringiensin (alternative name) [CCN] + TX, tolfenpyrad (809) + TX, tralomethrin (812) + TX, transfluthrin (813) + TX, transpermethrin (1440) + TX, triamiphos (1441 ) + TX, triazamate (818) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trichlormetaphos-3 (alternative name) [CCN] + TX, trichloronat (1452) + TX, trifenofos (1455) + TX, triflumuron (835) + TX, trimethacarb (840) + TX, triprene (1459) + TX, vamidothion (847) + TX, vaniliprole [CCN] + TX, veratridine (alternative name) (725) + TX, veratrine (alternative name) (725) + TX, XMC (853) + TX, xylylcarb (854) + TX, YI-5302 (compound code) + TX, zeta-cypermethrin (205) + TX, zetamethrin (alternative name) + TX, zinc phosphide (640) + TX, zolaprofos (1469) and ZXI 8901 (development code) (858) + TX, cyantraniliprole [736994-63-19] + TX, chlorantraniliprole [500008-45-7] + TX, cyenopyrafen [560121 -52-0] + TX, cyflumetofen [400882-07-7] + TX, pyrifluquinazon [337458-27-2] + TX, spinetoram [187166-40-1 + 187166-15-0] + TX, spirotetramat [203313-25-1 ] + TX, sulfoxaflor [946578-00-3] + TX, flufiprole [704886-18-0] + TX, meperfluthrin [915288-13-0] + TX,

tetramethylfluthrin [84937-88-2] + TX,

a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (lUPAC name) (913) + TX, bromoacetamide [CCN] + TX, calcium arsenate [CCN] + TX, cloethocarb (999) + TX, copper acetoarsenite [CCN] + TX, copper sulfate (172) + TX, fentin (347) + TX, ferric phosphate (lUPAC name) (352) + TX, metaldehyde (518) + TX, methiocarb (530) + TX, niclosamide (576) + TX, niclosamide-olamine (576) + TX, pentachlorophenol (623) + TX, sodium pentachlorophenoxide (623) + TX, tazimcarb (1412) + TX, thiodicarb (799) + TX, tributyltin oxide (913) + TX, trifenmorph (1454) + TX, trimethacarb (840) + TX, triphenyltin acetate (lUPAC name) (347) and triphenyltin hydroxide (lUPAC name) (347) + TX, pyriprole [394730-71 -3] + TX,

a nematicide selected from the group of substances consisting of AKD-3088 (compound code) + TX, 1 ,2-dibromo-3-chloropropane (lUPAC/Chemical Abstracts name) (1045) + TX, 1 ,2- dichloropropane (lUPAC/ Chemical Abstracts name) (1062) + TX, 1 ,2-dichloropropane with 1 ,3- dichloropropene (lUPAC name) (1063) + TX, 1 ,3-dichloropropene (233) + TX, 3,4- dichlorotetrahydrothiophene 1 ,1 -dioxide (lUPAC/Chemical Abstracts name) (1065) + TX, 3-(4- chlorophenyl)-5-methylrhodanine (lUPAC name) (980) + TX, 5-methyl-6-thioxo-1 ,3,5-thiadiazinan-3- ylacetic acid (lUPAC name) (1286) + TX, 6-isopentenylaminopurine (alternative name) (210) + TX, abamectin (1 ) + TX, acetoprole [CCN] + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, AZ 60541 (compound code) + TX, benclothiaz [CCN] + TX, benomyl (62) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, carbofuran (1 18) + TX, carbon disulfide (945) + TX, carbosulfan (1 19) + TX, chloropicrin (141 ) + TX, chlorpyrifos (145) + TX, cloethocarb (999) + TX, cytokinins (alternative name) (210) + TX, dazomet (216) + TX, DBCP (1045) + TX, DCIP (218) + TX, diamidafos (1044) + TX, dichlofenthion (1051 ) + TX, dicliphos (alternative name) + TX, dimethoate (262) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, eprinomectin (alternative name) [CCN] + TX, ethoprophos (312) + TX, ethylene dibromide (316) + TX, fenamiphos (326) + TX, fenpyrad (alternative name) + TX, fensulfothion (1 158) + TX, fosthiazate (408) + TX, fosthietan (1 196) + TX, furfural (alternative name) [CCN] + TX, GY-81

(development code) (423) + TX, heterophos [CCN] + TX, iodomethane (lUPAC name) (542) + TX, isamidofos (1230) + TX, isazofos (1231 ) + TX, ivermectin (alternative name) [CCN] + TX, kinetin (alternative name) (210) + TX, mecarphon (1258) + TX, metam (519) + TX, metam-potassium

(alternative name) (519) + TX, metam-sodium (519) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, Myrothecium verrucaha composition (alternative name) (565) + TX, NC-184 (compound code) + TX, oxamyl (602) + TX, phorate (636) + TX, phosphamidon (639) + TX, phosphocarb [CCN] + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachlorothiophene (lUPAC/ Chemical Abstracts name) (1422) + TX, thiafenox (alternative name) + TX, thionazin (1434) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, xylenols [CCN] + TX, YI-5302

(compound code) and zeatin (alternative name) (210) + TX, fluensulfone [318290-98-1 ] + TX,

a nitrification inhibitor selected from the group of substances consisting of potassium

ethylxanthate [CCN] and nitrapyrin (580) + TX,

a plant activator selected from the group of substances consisting of acibenzolar (6) + TX, acibenzolar-S-methyl (6) + TX, probenazole (658) and Reynoutha sachalinensis extract (alternative name) (720) + TX,

a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1 ,3-dione (lUPAC name) (1246) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (lUPAC name) (748) + TX, alpha-chlorohydrin [CCN] + TX, aluminium phosphide (640) + TX, antu (880) + TX, arsenous oxide (882) + TX, barium carbonate (891 ) + TX, bisthiosemi (912) + TX, brodifacoum (89) + TX,

bromadiolone (91 ) + TX, bromethalin (92) + TX, calcium cyanide (444) + TX, chloralose (127) + TX, chlorophacinone (140) + TX, cholecalciferol (alternative name) (850) + TX, coumachlor (1004) + TX, coumafuryl (1005) + TX, coumatetralyl (175) + TX, crimidine (1009) + TX, difenacoum (246) + TX, difethialone (249) + TX, diphacinone (273) + TX, ergocalciferol (301 ) + TX, flocoumafen (357) + TX, fluoroacetamide (379) + TX, flupropadine (1 183) + TX, flupropadine hydrochloride (1 183) + TX, gamma-HCH (430) + TX, HCH (430) + TX, hydrogen cyanide (444) + TX, iodomethane (lUPAC name) (542) + TX, lindane (430) + TX, magnesium phosphide (lUPAC name) (640) + TX, methyl bromide (537) + TX, norbormide (1318) + TX, phosacetim (1336) + TX, phosphine (lUPAC name) (640) + TX, phosphorus [CCN] + TX, pindone (1341 ) + TX, potassium arsenite [CCN] + TX, pyrinuron (1371 ) + TX, scilliroside (1390) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoro- acetate (735) + TX, strychnine (745) + TX, thallium sulfate [CCN] + TX, warfarin (851 ) and zinc phosphide (640) + TX,

a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (lUPAC name) (934) + TX, 5-(1 ,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (lUPAC name) (903) + TX, farnesol with nerolidol (alternative name) (324) + TX, MB-599 (development code) (498) + TX, MGK 264 (development code) (296) + TX, piperonyl butoxide (649) + TX, piprotal (1343) + TX, propyl isomer (1358) + TX, S421 (development code) (724) + TX, sesamex (1393) + TX, sesasmolin (1394) and sulfoxide (1406) + TX,

an animal repellent selected from the group of substances consisting of anthraquinone (32) + TX, chloralose (127) + TX, copper naphthenate [CCN] + TX, copper oxychloride (171 ) + TX, diazinon (227) + TX, dicyclopentadiene (chemical name) (1069) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, methiocarb (530) + TX, pyridin-4-amine (lUPAC name) (23) + TX, thiram (804) + TX, trimethacarb (840) + TX, zinc naphthenate [CCN] and ziram (856) + TX,

a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN] + TX,

a wound protectant selected from the group of substances consisting of mercuric oxide (512) + TX, octhilinone (590) and thiophanate-methyl (802) + TX,

and biologically active compounds selected from the group consisting of azaconazole (60207-

31 -0] + TX, bitertanol [70585-36-3] + TX, bromuconazole [1 16255-48-2] + TX, cyproconazole [94361 - 06-5] + TX, difenoconazole [1 19446-68-3] + TX, diniconazole [83657-24-3] + TX, epoxiconazole

[106325-08-0] + TX, fenbuconazole [1 14369-43-6] + TX, fluquinconazole [136426-54-5] + TX, flusilazole [85509-19-9] + TX, flutriafol [76674-21 -0] + TX, hexaconazole [79983-71 -4] + TX, imazalil [35554-44-0] + TX, imibenconazole [86598-92-7] + TX, ipconazole [125225-28-7] + TX, metconazole [1251 16-23-6] + TX, myclobutanil [88671 -89-0] + TX, pefurazoate [101903-30-4] + TX, penconazole [66246-88-6] + TX, prothioconazole [178928-70-6] + TX, pyrifenox [88283-41 -4] + TX, prochloraz [67747-09-5] + TX, propiconazole [60207-90-1 ] + TX, simeconazole [149508-90-7] + TX, tebuconazole [107534-96-3] + TX, tetraconazole [1 12281-77-3] + TX, triadimefon [43121 -43-3] + TX, triadimenol [55219-65-3] + TX, triflumizole [99387-89-0] + TX, triticonazole [131983-72-7] + TX, ancymidol [12771 - 68-5] + TX, fenarimol [60168-88-9] + TX, nuarimol [63284-71 -9] + TX, bupirimate [41483-43-6] + TX, dimethirimol [5221 -53-4] + TX, ethirimol [23947-60-6] + TX, dodemorph [1593-77-7] + TX, fenpropidine [67306-00-7] + TX, fenpropimorph [67564-91 -4] + TX, spiroxamine [1 18134-30-8] + TX, tridemorph [81412-43-3] + TX, cyprodinil [121552-61 -2] + TX, mepanipyrim [1 10235-47-7] + TX, pyrimethanil [531 12-28-0] + TX, fenpiclonil [74738-17-3] + TX, fludioxonil [131341 -86-1 ] + TX, benalaxyl [71626-1 1 - 4] + TX, furalaxyl [57646-30-7] + TX, metalaxyl [57837-19-1 ] + TX, R-metalaxyl [70630-17-0] + TX, ofurace [58810-48-3] + TX, oxadixyl [77732-09-3] + TX, benomyl [17804-35-2] + TX, carbendazim [10605-21 -7] + TX, debacarb [62732-91 -6] + TX, fuberidazole [3878-19-1 ] + TX, thiabendazole [148- 79-8] + TX, chlozolinate [84332-86-5] + TX, dichlozoline [24201 -58-9] + TX, iprodione [36734-19-7] + TX, myclozoline [54864-61 -8] + TX, procymidone [32809-16-8] + TX, vinclozoline [50471 -44-8] + TX, boscalid [188425-85-6] + TX, carboxin [5234-68-4] + TX, fenfuram [24691 -80-3] + TX, flutolanil [66332- 96-5] + TX, mepronil [55814-41 -0] + TX, oxycarboxin [5259-88-1 ] + TX, penthiopyrad [183675-82-3] + TX, thifluzamide [130000-40-7] + TX, guazatine [108173-90-6] + TX, dodine [2439-10-3] [1 12-65-2] (free base) + TX, iminoctadine [13516-27-3] + TX, azoxystrobin [131860-33-8] + TX, dimoxystrobin [149961 -52-4] + TX, enestroburin {Proc. BCPC, Int. Congr., Glasgow, 2003, 1 , 93} + TX, fluoxastrobin [361377-29-9] + TX, kresoxim-methyl [143390-89-0] + TX, metominostrobin [133408-50-1 ] + TX, trifloxystrobin [141517-21 -7] + TX, orysastrobin [248593-16-0] + TX, picoxystrobin [1 17428-22-5] + TX, pyraclostrobin [175013-18-0] + TX, ferbam [14484-64-1 ] + TX, mancozeb [8018-01 -7] + TX, maneb [12427-38-2] + TX, metiram [9006-42-2] + TX, propineb [12071 -83-9] + TX, thiram [137-26-8] + TX, zineb [12122-67-7] + TX, ziram [137-30-4] + TX, captafol [2425-06-1 ] + TX, captan [133-06-2] + TX, dichlofluanid [1085-98-9] + TX, fluoroimide [41205-21 -4] + TX, folpet [133-07-3 ] + TX, tolylfluanid [731 - 27-1 ] + TX, bordeaux mixture [801 1 -63-0] + TX, copperhydroxid [20427-59-2] + TX, copperoxychlorid [1332-40-7] + TX, coppersulfat [7758-98-7] + TX, copperoxid [1317-39-1 ] + TX, mancopper [53988-93- 5] + TX, oxine-copper [10380-28-6] + TX, dinocap [131-72-6] + TX, nitrothal-isopropyl [10552-74-6] + TX, edifenphos [17109-49-8] + TX, iprobenphos [26087-47-8] + TX, isoprothiolane [50512-35-1 ] + TX, phosdiphen [36519-00-3] + TX, pyrazophos [13457-18-6] + TX, tolclofos-methyl [57018-04-9] + TX, acibenzolar-S-methyl [135158-54-2] + TX, anilazine [101 -05-3] + TX, benthiavalicarb [413615-35-7] + TX, blasticidin-S [2079-00-7] + TX, chinomethionat [2439-01 -2] + TX, chloroneb [2675-77-6] + TX, chlorothalonil [1897-45-6] + TX, cyflufenamid [180409-60-3] + TX, cymoxanil [57966-95-7] + TX, dichlone [117-80-6] + TX, diclocymet [139920-32-4] + TX, diclomezine [62865-36-5] + TX, dicloran [99- 30-9] + TX, diethofencarb [87130-20-9] + TX, dimethomorph [110488-70-5] + TX, SYP-LI90

(Flumorph) [211867-47-9] + TX, dithianon [3347-22-6] + TX, ethaboxam [162650-77-3] + TX, etridiazole [2593-15-9] + TX, famoxadone [131807-57-3] + TX, fenamidone [161326-34-7] + TX, fenoxanil [115852-48-7] + TX, fentin [668-34-8] + TX, ferimzone [89269-64-7] + TX, fluazinam [79622- 59-6] + TX, fluopicolide [2391 10-15-7] + TX, flusulfamide [106917-52-6] + TX, fenhexamid [126833-17- 8] + TX, fosetyl-aluminium [39148-24-8] + TX, hymexazol [10004-44-1 ] + TX, iprovalicarb [140923-17- 7] + TX, IKF-916 (Cyazofamid) [120116-88-3] + TX, kasugamycin [6980-18-3] + TX, methasulfocarb [66952-49-6] + TX, metrafenone [220899-03-6] + TX, pencycuron [66063-05-6] + TX, phthalide [27355- 22-2] + TX, polyoxins [1 1 1 13-80-7] + TX, probenazole [27605-76-1 ] + TX, propamocarb [25606-41 -1 ] + TX, proquinazid [189278-12-4] + TX, pyroquilon [57369-32-1 ] + TX, quinoxyfen [124495-18-7] + TX, quintozene [82-68-8] + TX, sulphur [7704-34-9] + TX, tiadinil [223580-51 -6] + TX, triazoxide [72459-58- 6] + TX, tricyclazole [41814-78-2] + TX, triforine [26644-46-2] + TX, validamycin [37248-47-8] + TX, zoxamide (RH7281 ) [156052-68-5] + TX, mandipropamid [374726-62-2] + TX, isopyrazam [881685-58- 1 ] + TX, sedaxane [874967-67-6] + TX, 3-difluoromethyl-1 -methyl-1 H-pyrazole-4-carboxylic acid (9- dichloromethylene-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl)-amide (dislosed in WO

2007/048556) + TX, 3-difluoromethyl-1 -methyl-1 H-pyrazole-4-carboxylic acid [2-(2,4-dichlorophenyl)-2- methoxy-1 -methyl-ethyl]-amide (disclosed in WO 2008/148570) + TX, 1 -[4-[4-[(5S)5-(2,6- difluorophenyl)-4,5-dihydro-1 ,2-oxazol-3-yl]-1 ,3-thiazol-2-yl]piperidin-1 -yl]-2-[5-methyl-3- (trifluoromethyl)-l H-pyrazol-1 -yl]ethanone + TX, 1 -[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-1 ,2-oxazol- 3-yl]-1 ,3-thiazol-2-yl]piperidin-1 -yl]-2-[5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1 -yl]ethanone [1003318- 67-9], both disclosed in WO 2010/123791 , WO 2008/013925, WO 2008/013622 and WO 201 1/051243 page 20) +TX, and 3-difluoromethyl-1 -methyl-1 H-pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl- 2-yl)-amide (dislosed in WO 2006/087343) + TX.

The references in square brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in "The Pesticide Manual" [The Pesticide Manual - A World

Compendium; Thirteenth Edition; Editor: C. D. S. Tomlin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound "abamectin" is described under entry number (1 ). Where "[CCN]" is added hereinabove to the particular compound, the compound in question is included in the "Compendium of Pesticide Common Names", which is accessible on the internet [A. Wood;

Compendium of Pesticide Common Names, Copyright © 1995-2004]; for example, the compound "acetoprole" is described under the internet address:

http://www.alanwood.net/pesticides/acetoprole.html.

Most of the active ingredients described above are referred to hereinabove by a so-called "common name", the relevant "ISO common name" or another "common name" being used in individual cases. If the designation is not a "common name", the nature of the designation used instead is given in round brackets for the particular compound; in that case, the lUPAC name, the

lUPAC/Chemical Abstracts name, a "chemical name", a "traditional name", a "compound name" or a "develoment code" is used or, if neither one of those designations nor a "common name" is used, an "alternative name" is employed. "CAS Reg. No" means the Chemical Abstracts Registry Number.

The mass ratio of of any two ingredients in each combination is selected as to give the desired, for example, synergistic action. In general, the mass ratio would vary depending on the specific ingredient and how many ingredients are present in the combination. Generally, the mass ratio between any two ingredients in any combination of the present invention, independently of one another, is from 100:1 to 1 :100, including from 99:1 , 98:2, 97:3, 96:4, 95:5, 94:6, 93:7, 92:8, 91 :9, 90:10, 89:11 , 88:12, 87:13, 86:14, 85:15, 84:16, 83:17, 82:18, 81 :19, 80:20, 79:21 , 78:22, 77:23, 76:24, 75:25, 74:26, 73:27, 72:28, 71 :29, 70:30, 69:31 , 68:32, 67:33, 66:34, 65:45, 64:46, 63:47, 62:48, 61 :49, 60:40, 59:41 , 58:42, 57:43, 56:44, 55:45, 54:46, 53:47, 52:48, 51 :49, 50:50, 49:51 , 48:52, 47:53, 46:54, 45:55, 44:56, 43:57, 42:58, 41 :59, 40:60, 39:61 , 38:62, 37:63, 36:64, 35:65, 34:66, 33:67, 32:68, 31 :69, 30:70, 29:71 , 28:72, 27:73, 26:74, 25:75, 24:76, 23:77, 22:78, 21 :79, 20:80, 19:81 , 18:82, 17:83, 16:84, 15:85, 14:86, 13:87, 12:88, 1 1 :89, 10:90, 9:91 , 8:92, 7:93, 6:94, 5:95, 4:96, 3:97, 2:98, to 1 :99. Preferred mass ratios between any two components of present invention are from 75:1 to 1 :75, more preferably, 50:1 to 1 .50, especially 25:1 to 1 :25, advantageously 10:1 to 1 :10, such as 5:1 to 1 :5, for example 1 :3 to 3:1 . The mixing ratios are understood to include, on the one hand, ratios by mass and also, on other hand, molar ratios. The combinations of the present invention (i.e. those comprising a compound of the present invention and one or more other biological active agents) may be applied simulatenously or sequentially.

In the event, the ingredients of a combination are applied sequentially (i.e., one after the other), the ingredients are applied sequentially within a reasonable period of each other to attain the biological performance, such as within a few hours or days. The order of applying the ingredients in the combination, i.e., whether the compounds of formula (I) should be applied first or not is not essential for working the present invention.

In the event ingredients of the combinations are applied simultaneously in the present invention, they may be applied as a composition containing the combination, in which case (A) the compound of formula (I) and the one or more other ingredients in the combinations can be obtained from separate formulation sources and mixed together (known as a tank-mix, ready-to-apply, spray broth, or slurry), or (B) the compound of formula (I) and the one or more other ingredients can be obtained as single formulation mixture source (known as a pre-mix, ready-mix, concentrate, or formulated product).

In an embodiment, independent of other embodiments, a compound according to the present invention is applied as a combination. Accordingly, the present invention also provides a composition comprising a a compound according the invention as herein described and one or more other biological active agents, and optionally one or more customary formulation auxiliaries; which may be in the form of a tank-mix or pre-mix composition.

The compounds of formula (I) are particularly useful for controlling and preventing helminth and nemtode endo- and ectoparasitic infestations and infections in warm-blooded animals such as cattle, sheep, swine, camels, deer, horses, poultry, fish, rabbits, goats, mink, fox, chinchillas, dogs and cats as well as humans.

In the context of control and prevention of infestation and infections in warm-blooded animals, compounds of invention are especially useful for the control of helminths and nematodes. Examples for helminths are members of the class Trematoda, commonly known as flukes or flatworms, especially members of the genera Fasciola, Fascioloides, Paramphistomu, Dicrocoelium, Eurytrema, Ophisthorchis, Fasciolopsis, Echinostoma and Paragonimus. Nematodes which can be controlled by the formula (I) compounds include the genera Haemonchus, Ostertagia, Cooperia, Oesphagastomu, Nematodirus, Dictyocaulus, Trichuris, Dirofilaria, Ancyclostoma, Ascaria and the like.

For oral administration to warm-blooded animals, the compounds of the invention may be formulated as animal feeds, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, drenches, gels, tablets, boluses and capsules. In addition, the compounds of the invention may be administered to the animals in their drinking water. For oral administration, the dosage form chosen should provide the animal with about 0.01 mg/kg to 100 g/kg of animal body weight per day of the compound of the invention.

Alternatively, the compounds of the invention may be administered to animals parenterally, for example, by intraruminal, intramuscular, intravenous or subcutaneous injection. The compounds of the invention may be dispersed or dissolved in a physiologically acceptable carrier for subcutaneous injection. Alternatively, the compounds of the invention may be formulated into an implant for subcutaneous administration. In addition the compounds of the invention may be transdermally administered to animals. For parenteral administration, the dosage form chosen should provide the animal with about 0.01 mg/kg to 100 mg/kg of animal body weight per day of the compound of the invention.

The compounds of the invention may also be applied topically to the animals in the form of dips, dusts, powders, collars, medallions, sprays and pour-on formulations. For topical application, dips and sprays usually contain about 0.5 ppm to 5,000 ppm and preferably about 1 ppm to 3,000 ppm of the compound of the invention. In addition, the compounds of the invention may be formulated as ear tags for animals, particularly quadrupeds such as cattle and sheep.

In an embodiment, independent of any other embodiments, a compound of formula (I) is a anti- helminth compound.

In an embodiment, independent of any other embodiments, a compound of formula (I) is a pesticidal compound, preferably a nematicidal compound.

In each aspect and embodiment of the invention, "consisting essentially" and inflections thereof are a preferred embodiment of "comprising" and its inflections, and "consisting of and inflections thereof are a preferred embodiment of "consisting essentially of and its inflections.

The following Examples serve to illustrate the invention. They do not limit the invention.

Temperatures are given in degrees Celsius; mixing ratios of solvents are given in parts by volume.

Preparation examples

Example P1 : Preparation of racemic V-(c;s-2-(5-fluoronaphthalen-1 -yl)cvclobutyl)-2- (trifluoromethyl) benzamide

Step a: Preparation of 1 -(cvclopropylidenemethyl)-5-fluoronaphthalene

To a suspension of (3-bromopropyl)triphenylphosphonium bromide (16.0 g, 33.8 mmol) in anhydrous THF (1 15 mL) was added potassium i-butoxide (7.75 g, 67.7 mmol) in four separate portions 15 min apart. The mixture was then heated to reflux for 10 min and 5-fluoro-1 -naphthaldehyde (5.01 g, 28.2 mmol) was added portionwise, then continued at reflux for 6 hours. The reaction mixture was cooled down to room temperature and stirred overnight, then filtered through a Celite pad and washed with hexanes. The filtrate was concentrated, and the residue was purified by column chromatography on silica gel (hexanes), affording 1 -(cyclopropylidenemethyl)-5-fluoronaphthalene as a colorless oil.

H NMR (300 MHz, CDCI ₃ ) δ 8.01 (t, J = 8.3 Hz, 2H), 7.91 (d, J = 7.2 Hz, 1 H), 7.58 - 7.36 (m, 3H), 7.15 (dd, J = 10.4, 7.7 Hz, 1 H), 1.51 - 1 .39 (m, 2H), 1 .36 - 1 .22 (m, 2H) ppm.

Step b: Preparation of racemic 2-(5-fluoronaphthalen-1 -yl)cvclobutanone

To a solution of 1 -(cyclopropylidenemethyl)-5-fluoronaphthalene (4.90 g, 24.7 mmol) in CH ₂ CI ₂

(135 mL) was added m-chloroperbenzoic acid (ca 77%, 6.65 g, 29.7 mmol) at 0°C. After stirring at 0°C for 1 hour, the reaction mixture was allowed to warm to room temperature and stirred overnight. The mixture was washed twice with saturated NaHC0 ₃ aqueous solution (2 x 150 mL) and brine (150 mL), dried over Na ₂ S0 ₄ and concentrated. The residue was purified by column chromatography on silica gel (hexanes:EtOAc 9:1 ) affording 2-(5-fluoronaphthalen-1-yl)cyclobutanone as a white solid .

m.p. 67-68°C

H NMR (300 MHz, CDCI ₃ ) δ 8.05 (d, J = 8.3 Hz, 1 H), 7.72 (d, J = 8.6 Hz, 1 H), 7.57 (d, J = 7.1 Hz, 1 H), 7.50 (d, J = 8.1 Hz, 1 H), 7.50 - 7.39 (m, 1 H), 7.18 (dd, J = 10.2, 7.8 Hz, 1 H), 5.16 (dd, J = 10.1 , 8.4 Hz, 1 H), 3.33 (dddd, J = 18.2, 10.4, 8.1 , 2.4 Hz, 1 H), 3.15 (dddd, J = 17.7, 9.8, 5.1 , 2.4 Hz, 1 H), 2.73 (ddd, J = 21 .3, 10.5, 5.1 Hz, 1 H), 2.44 - 2.24 (m, 1 H) ppm.

Step c: Preparation of a mixture of racemic (E)- and (Z)-2-(5-fluoronaphthalen-1 - vDcvclobutanone oximes

To a solution of racemic 2-(5-fluoronaphthalen-1-yl)cyclobutanone (2.90 g, 13.5 mmol) in methanol (60 mL), sodium acetate (1 .26 g, 14.9 mmol) and hydroxylamine hydrochloride (1 .05 g, 14.9 mmol) were added. The mixture was stirred at room temperature overnight. Reaction mixture was concentrated. To the crude material was added water (150 mL) and suspension was stirred for 3 hours, solid was filtered off, washed with another portion of water and dried under vacuum to afford a mixture of racemic (E)- and (Z)-2-(5-fluoronaphthalen-1 -yl)cyclobutanone oximes as a white solid.

H NMR (300 MHz, CDCI ₃ ) δ 8.04 (d, J = 8.4 Hz, 1 H), 7.74 (d, J = 7.1 Hz, 1 H), 7.67 (d, J = 8.5 Hz, 1 H), 7.46 (ddd, J = 14.1 , 9.7, 6.8 Hz, 2H), 7.17 (dd, J = 10.3, 7.8 Hz, 1 H), 5.05 (t, J = 8.2 Hz, 1 H), 3.22 - 2.96 (m, 2H), 2.81 - 2.63 (m, 1 H), 2.24 - 2.08 (m, 1 H) ppm.

Step d : Preparation of racemic cis- and frans-2-(5-fluoronaphthalen-1 -yl)cvclobutanamines To a suspension of Raney nickel (approx. 3.1 g of a 50% suspension in water ) in ammonia solution (7 M in MeOH, 130 mL) was added a mixture of racemic (E)- and (Z)-2-(5-fluoronaphthalen-1 - yl)cyclobutanone oximes (3.05 g, 13.3 mmol). The mixture was stirred under an atmosphere of hydrogen at room temperature for 18 hours. The catalyst was removed by filtration through a Celite pad and washed with CH ₂ CI ₂ . The filtrate was concentrated, and the residue was purified by column chromatography on silica gel (CH ₂ CI ₂ :MeOH 95:5) affording racemic c; ^' s-2-(5-fluoronaphthalen-1 - yl)cyclobutanamine as an yellow oil and racemic irans-2-(5-fluoronaphthalen-1-yl)cyclobutanamine as a yellow viscous oil.

Racemic c;s-2-(5-fluoronaphthalen-1-yl)cyclobutanamine: H NMR (300 MHz, CDCI ₃ ) 68.04 (d, J= 8.2 Hz, 1H), 7.71 (d, J= 8.6 Hz, 1H), 7.60-7.37 (m, 3H), 7.16 (ddd, J= 10.4, 7.7, 0.8 Hz, 1H), 4.41 -4.27 (m, 1H), 4.16-4.04 (m, 1H), 2.70-2.45 (m, 2H), 2.31 (dddd, J= 13.0, 11.7, 7.9, 2.2 Hz, 1H), 1.87-1.71 (m, 1H), 1.11 (brs, NH ₂ ) ppm.

Racemic irans-2-(5-fluoronaphthalen-1-yl)cyclobutanamine: H NMR (300 MHz, CDCI ₃ ) δ 7.98 (dd, J= 7.6, 1.5 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.53-7.33 (m, 3H), 7.12 (ddd, J= 10.4, 7.7, 0.7 Hz, 1H), 3.84 (dd, J= 18.1, 8.7 Hz, 1H), 3.70 (dd, J= 16.5, 8.3 Hz, 1H), 3.19 (brs, NH ₂ ), 2.41 -2.22 (m, 2H), 1.99 -1.66 (m,2H) ppm.

Step e: Preparation of racemic c;s-2-(5-fluoronaphthalen-1-yl)cvclobutanamine hydrochloride

To a solution of racemic c; ^' s-2-(5-fluoronaphthalen-1-yl)cyclobutanamine (1.71 g, 7.15 mmol) in CH ₂ CI ₂ (22 mL) was added dropwise 4M HCI in dioxane (11 mL, 42.9 mmol) at 0°C under inert atmosphere. The reaction mixture was stirred at room temperature for 4 hours, then it was concentrated and the residue was triturated with Et ₂ 0:CH ₂ CI ₂ (50:5 mL) for 1 hr at room temperature, then suspension was cool down in ice bath and a precipitate was filtered off, washed with smaller amount of Et ₂ 0 and dried under vacuum to give the racemic c; ^' s-2-(5-fluoronaphthalen-1- yl)cyclobutanamine hydrochloride as a white solid.

m.p.252-254°C (with dec.)

H NMR (300 MHz, CDCI ₃ ) 67.99 (d, J= 8.3 Hz, 1H), 7.68-7.37 (br s + m, NH ₃ + 4H), 7.17

(ddd, J= 10.4, 5.9, 2.7 Hz, 1H), 4.36 (dd, J= 16.1, 8.3 Hz, 1H), 3.94-2.78 (m, 1H), 3.05-2.86 (m, 1H), 2.44 -2.18 (m,2H), 1.67-1.49 (m, 1H)ppm.

Step f: Preparation of racemic A/-(c/s-2-(5-fluoronaphthalen-1-yl)cvclobutyl)-2- (trifluoromethyl)benzamide

To racemic c; ^' s-2-(5-fluoronaphthalen-1-yl)cyclobutanamine hydrochloride (141 mg, 0.55 mmol) and triethylamine (0.19 mL, 1.38 mmol) in anhydrous THF (4.5 mL) was added dropwise 2- (trifluoromethyl)benzoyl chloride (0.09 mL, 0.61 mmol) in anhydrous THF (1.5 mL) at 0°C under inert atmosphere. The reaction mixture was stirred at room temperature for 5 hours. Triethylamine hydrochloride was filtered off, washed with small amount of Et ₂ 0. Filtrate was concentrated and purified by column chromatography on silica gel (hexanes:EtOAc 5:1 ) affording N-(cis-2-(5- fluoronaphthalen-1-yl)cyclobutyl)-2-(trifluoromethyl)benzami de as a white solid .

m.p.124-126°C

H NMR (300 MHz, CDCI ₃ ) δ 8.07 (d, J = 7.5 Hz, 1 H), 7.78 (d, J = 8.6 Hz, 1 H), 7.63 - 7.42 (m, 4H), 7.32 (t, J = 7.7 Hz, 1H), 7.24-7.14 (m, 2H), 6.23 (d, J= 7.6 Hz, 1H), 5.35-5.15 (m, NH + 1H), 4.72 - 4.58 (m, 1 H), 2.78 - 2.54 (m, 2H), 2.52 - 2.36 (m, 1 H), 2.22 - 2.03 (m, 1 H) ppm.

Table 113: Compounds of formula (lie)

Table 113 shows selected melting point, selected HPLC-MS, selected GC-MS and selected NMR data for compounds (lie) or their hydrochloride salt of the present invention. CDCI ₃ was used as the solvent for NMR measurements, unless otherwise stated. No attempt is made to list all characterising data in all cases. All retention times (Rt) and [M+H] were measured using 'Method A' below.

(He)

In Table 1 13 and throughout the description that follows, temperatures are given in degrees Celsius; "NMR" means nuclear magnetic resonance spectrum; HPLC is high pressure liquid chromatography; GC stands for gas chromatography, MS stands for mass spectrum; "%" is percent by weight, unless corresponding concentrations are indicated in other units. The following abbreviations are used throughout this description:

melting point [°C] boiling point,

singlet broad

doublet doublet of doublets triplet quartet

multiplet parts per million

Table 1 14: Compounds of formula (I)

Table 1 14 shows selected melting point, selected HPLC-MS, and selected NMR data for compounds (I) of the present invention. CDCI ₃ was used as the solvent for NMR measurements, unless otherwise stated. No attempt is made to list all characterising data in all cases. All retention times (Rt) and [M+H] were measured using 'Method A' below.

Entry lUPAC name Rt [M+H] M.P.(°C)

(min) (measured)

1 14-1 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-2- 138

(trifluoromethyl)benzamide

1 14-2 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-3- 171

(trifluoromethyl)pyridine-2-carboxamide Entry lUPAC name Rt [M+H] M.P.(°C)

(min) (measured)

1 14-3 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-2- 153

(trifluoromethyl)pyridine-3-carboxamide

1 14-4 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-3- 143

(trifluoromethyl)pyrazine-2-carboxamide

1 14-5 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-2- 1 10 chloropyridine-3-carboxamide

1 14-6 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-3- 141 chloropyrazine-2-carboxamide

1 14-7 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-2,6- 61 difluorobenzamide

1 14-8 N-[cis-2-(6-bromonaphthalen-2-yl)cyclobutyl]-3- 137 chloropyridine-2-carboxamide

1 14-9 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-2- 149

(trifluoromethyl)benzamide

1 14-10 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-3- 139

(trifluoromethyl)pyridine-2-carboxamide

1 14-1 1 N-[cis-2-(4-fluoronaphthalen-1 -yl)cyclobutyl]-2- 120-122

(trifluoromethyl)benzamide

1 14-12 N-[cis-2-(4-fluoronaphthalen-1 -yl)cyclobutyl]-2- 189-191

(trifluoromethyl)pyridine-3-carboxamide

1 14-13 N-[cis-2-(4-fluoronaphthalen-1 -yl)cyclobutyl]-3- 128-129

(trifluoromethyl)pyridine-2-carboxamide

1 14-14 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-2- 223

(trifluoromethyl)pyridine-3-carboxamide

1 14-15 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-3- 169

(trifluoromethyl)pyrazine-2-carboxamide

1 14-16 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-2- 189 chloropyridine-3-carboxamide

1 14-17 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-3- 139 chloropyrazine-2-carboxamide

1 14-18 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-2,6- 154 difluorobenzamide

1 14-19 N-[cis-2-(4-bromonaphthalen-1 -yl)cyclobutyl]-3- 167 chloropyridine-2-carboxamide

1 14-20 N-[cis-2-(4-fluoronaphthalen-1 -yl)cyclobutyl]-3- 1 18-1 19

(trifluoromethyl)pyrazine-2-carboxamide

1 14-21 2-chloro-N-[cis-2-(4-fluoronaphthalen-1 - 164-165 yl)cyclobutyl]pyridine-3-carboxamide

1 14-22 3-chloro-N-[cis-2-(4-fluoronaphthalen-1 - 131 -133 yl)cyclobutyl]pyrazine-2-carboxamide

1 14-23 2,6-difluoro-N-[cis-2-(4-fluoronaphthalen-1 - 154-155 yl)cyclobutyl]benzamide

1 14-24 3-chloro-N-[cis-2-(4-fluoronaphthalen-1 - 157-158 yl)cyclobutyl]pyridine-2-carboxamide

1 14-25 N-[cis-2-naphthalen-1 -ylcyclobutyl]-2- 1 19-121

(trifluoromethyl)benzamide

1 14-26 N-[cis-2-(5-fluoronaphthalen-1 -yl)cyclobutyl]-2- 124-126

(trifluoromethyl)benzamide

1 14-27 N-[cis-2-naphthalen-1 -ylcyclobutyl]-2- 205-207

(trifluoromethyl)pyridine-3-carboxamide

1 14-28 N-[cis-2-(5-fluoronaphthalen-1 -yl)cyclobutyl]-2- 139-140

(trifluoromethyl)pyridine-3-carboxamide

1 14-29 N-[cis-2-naphthalen-1 -ylcyclobutyl]-3- 127-128

(trifluoromethyl)pyridine-2-carboxamide

1 14-30 N-[cis-2-(5-fluoronaphthalen-1 -yl)cyclobutyl]-3- 135-136

(trifluoromethyl)pyridine-2-carboxamide Entry lUPAC name Rt [M+H] M.P.(°C)

(min) (measured)

1 14-31 N-[cis-2-naphthalen-1 -ylcyclobutyl]-3- 125-126

(trifluoromethyl)pyrazine-2-carboxamide

1 14-32 N-[cis-2-(5-fluoronaphthalen-1 -yl)cyclobutyl]-3- 136-137

(trifluoromethyl)pyrazine-2-carboxamide

1 14-33 2-chloro-N-[cis-2-naphthalen-1 - 147-149 ylcyclobutyl]pyridine-3-carboxamide

1 14-34 2-chloro-N-[cis-2-(5-fluoronaphthalen-1 - 105-106 yl)cyclobutyl]pyridine-3-carboxamide

1 14-35 3-chloro-N-[cis-2-naphthalen-1 - 147-149 ylcyclobutyl]pyrazine-2-carboxamide

1 14-36 3-chloro-N-[cis-2-(5-fluoronaphthalen-1 - 148-149 yl)cyclobutyl]pyrazine-2-carboxamide

1 14-37 2,6-difluoro-N-[cis-2-naphthalen-1 - 197-198 ylcyclobutyl]benzamide

1 14-38 2,6-difluoro-N-[cis-2-(5-fluoronaphthalen-1 - 158-159 yl)cyclobutyl]benzamide

1 14-39 3-chloro-N-[cis-2-naphthalen-1 - 137-138 ylcyclobutyl]pyridine-2-carboxamide

1 14-40 3-chloro-N-[cis-2-(5-fluoronaphthalen-1 - 147-148 yl)cyclobutyl]pyridine-2-carboxamide

1 14-41 N-[cis-2-(6-fluoronaphthalen-2-yl)cyclobutyl]-2- 147-148

(trifluoromethyl)benzamide

1 14-42 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-2- 149-151

(trifluoromethyl)benzamide

1 14-43 N-[cis-2-(6-fluoronaphthalen-2-yl)cyclobutyl]-2- 132-133

(trifluoromethyl)pyridine-3-carboxamide

1 14-44 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-2- 131 -133

(trifluoromethyl)pyridine-3-carboxamide

1 14-45 N-[cis-2-(6-fluoronaphthalen-2-yl)cyclobutyl]-3- 1 .10 389

(trifluoromethyl)pyridine-2-carboxamide

1 14-46 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-3- 126-127

(trifluoromethyl)pyridine-2-carboxamide

1 14-47 2-chloro-N-[cis-2-(6-fluoronaphthalen-2- 0.99 355

yl)cyclobutyl]pyridine-3-carboxamide

1 14-48 3-chloro-N-[cis-2-(6-fluoronaphthalen-2- 1 16-1 17 yl)cyclobutyl]pyrazine-2-carboxamide

1 14-49 N-[cis-2-(6-fluoronaphthalen-2-yl)cyclobutyl]-3- 109-1 10

(trifluoromethyl)pyrazine-2-carboxamide

1 14-50 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-3- 1 .12 450

(trifluoromethyl)pyrazine-2-carboxamide

1 14-51 2,6-difluoro-N-[cis-2-(6-fluoronaphthalen-2- 133-134 yl)cyclobutyl]benzamide

1 14-52 3-chloro-N-[cis-2-(6-fluoronaphthalen-2- 1 .05 355

yl)cyclobutyl]pyridine-2-carboxamide

1 14-53 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-2- 170-171 chloropyridine-3-carboxamide

1 14-54 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-3- 179-180 chloropyrazine-2-carboxamide

1 14-55 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-2,6- 21 1 -212 difluorobenzamide

1 14-56 N-[cis-2-naphthalen-2-ylcyclobutyl]-2- 137-138

(trifluoromethyl)benzamide

1 14-57 N-[cis-2-naphthalen-2-ylcyclobutyl]-2- 147-148

(trifluoromethyl)pyridine-3-carboxamide

1 14-58 N-[cis-2-naphthalen-2-ylcyclobutyl]-3- 1 .09 371

(trifluoromethyl)pyridine-2-carboxamide Entry lUPAC name Rt [M+H] M.P.(°C)

(min) (measured)

1 14-59 N-[cis-2-naphthalen-2-ylcyclobutyl]-3- 89-90

(trifluoromethyl)pyrazine-2-carboxamide

1 14-60 2-chloro-N-[cis-2-naphthalen-2- 138-139 ylcyclobutyl]pyridine-3-carboxamide

1 14-61 3-chloro-N-[cis-2-naphthalen-2- 125-126 ylcyclobutyl]pyrazine-2-carboxamide

1 14-62 2,6-difluoro-N-[cis-2-naphthalen-2- 157-158 ylcyclobutyl]benzamide

1 14-63 3-chloro-N-[cis-2-naphthalen-2- 1 .04 337

ylcyclobutyl]pyridine-2-carboxamide

1 14-64 N-[cis-2-(1 -bromonaphthalen-2-yl)cyclobutyl]-3- 130-132 chloropyridine-2-carboxamide

Table 1 15: Compounds of formula (lab)

Table 1 15 shows selected melting point, selected HPLC-MS for compounds of the present invention. No attempt is made to list all characterising data in all cases.

RT refers to the retention time of the HPLC-MS method and RT' refers to the retention time of the desired enantiomer in the chiral HPLC method. Compounds 1 15-1 was obtained through the resolution of its racemate via preparative chiral HPLC.

Retention times (Rt) and [M+H] were measured using 'Method A' below. The chiral retention time (Rf) was measured using 'Method B' below.

Method A

Spectra were recorded on a Mass Spectrometer from Waters (SQD or ZQ Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive or negative ions, Capillary: 3.00 kV, Cone range: 30-60 V, Extractor: 2.00 V, Source Temperature: 150°C, Desolvation Temperature: 350°C, Cone Gas Flow: 0 L/Hr, Desolvation Gas Flow: 650 L/Hr, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment and diode-array detector. Solvent degasser, binary pump, heated column compartment and diode-array detector. Column: Waters UPLC HSS T3, 1 .8 Lm, 30 x 2.1 mm, Temp: 60 °C, DAD Wavelength range (nm): 210 to 500, Solvent Gradient: A = water + 5% MeOH + 0.05% HCOOH, B= Acetonitrile + 0.05% HCOOH: gradient: gradient: 0 min 0% B, 100%A; 1 .2-1 .5min 100% B; Flow (ml/min) 0.85

Method B (chiral)

Waters UPLC - HCIass from Waters: solvent degasser, quaternary pump and PDA detector Column: Chiralpak IC, length (mm) 100, internal diameter (mm) 4.6, particle size (μ) 3, wavelength (nm): 290 nm, solvent: Isocratic Heptane: EtOH 80:20, injection volume 2μΙ, flow (ml/min) 1 .0

Biological examples:

Heterodera schachtii (Sugar beet cyst nematode), Nematicide, contact activity The tested application rate of each compound was 20 ppm. All solutions were brought to a concentration of 40 ppm, respectively, as they were subsequently diluted by adding the equivalent amount of water containing juvenile nematodes. After preparation of the suspensions, 1 mL of each suspension and concentration was transferred to 16-well assay plates with a total of three replicates per treatment. Approximately 500 juveniles of Heterodera schachtii were added in 1 mL of water to each well. Nematodes in water served as controls. The plates were placed in a dark box and stored at room temperature. Nematode paralysis was determined after 24 hours incubation at 25°C in darkness. Nematodes that showed no movement were considered immotile.

The following compounds showed a greater than 75% nematode immobilization compared to the untreated control: 1 14-3, 1 14-1 1 , 1 14-26, 1 14-42, 1 14-44, 1 14-45, 1 14-50, 1 15-1 .

Meloidogyne spp. (Root-knot nematode), Nematicide, contact activity, preventive

Filter papers (9 cm x 4.5 cm) with a small pocket were placed into plastic pouches (12 cm x 6 cm ). One cucumber cv. Toshka seed was placed in the centre of the filter paper pocket of all the pouches needed for a test. The cucumber seeds in the pouches were treated with test solutions at 200 ppm by pipetting the solution directly over the cucumber seed in the filter paper pocket in the pouch. Prior to application, the compound solution was prepared at twice the concentration required and the egg suspension is prepared with FORL nutrient solution with 3000 eggs/ 0.5 mL. After applying all the treatments, 3000 eggs (in 0.5 mL of FORL nutrient solution) were pipetted into the pouches. The pouches were incubated in a moist chamber for twelve days and watered regularly to maintain good filter paper moisture essential for the growing cucumber root system. After this period, the filter paper containing the germinated cucumber seedling was removed from the plastic pouch to assess the number of galls caused by Meloidogyne spp. per root system.

The following compounds showed a greater than 80% reduction of galling compared to the untreated control: 1 14-7, 1 14-1 1 , 1 14-17, 1 14-20, 1 14-25, 1 14-35.

Meloidogyne spp. (Root-knot nematode), Nematicide, contact activity, preventive

Cucumber cv. Toshka seeds were sown directly into pots filled with a sandy substrate. Six days later pots were each treated with 5 mL of a WP10 suspension of the test compound. Hereafter, pots were inoculated with 3000 eggs of M. incognita. The trial was harvested fourteen days after trial application and inoculation. Root galling was assessed according to Zeck ^' s gall index (Zeck W.M. (1971 ) Ein Bonitierungsschema zur Feldauswertung von Wurzelgallenbefall.

Pflanzenschutznachrichten Bayer 24,1 : 144-147.). The following compounds showed a greater than 80% reduction of galling compared to the untreated control: 1 14-7, 1 14-13, 1 14-18, 1 14-20, 1 14-21 , 1 14-22, 1 14-23, 1 14-25.